Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7669958,Need for,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,9.6,1547,DB00368,Norepinephrine
,7669958,Need for,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,41.6,1548,DB00368,Norepinephrine
,7669958,NE,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,9.6,1549,DB00368,Norepinephrine
,7669958,NE,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,41.6,1550,DB00368,Norepinephrine
,7669958,Need,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,16.0,1551,DB00368,Norepinephrine
,7669958,Need,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,232.5,1552,DB00368,Norepinephrine
,7669958,NE,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,16.0,1553,DB00368,Norepinephrine
,7669958,NE,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,232.5,1554,DB00368,Norepinephrine
,3117068,duration of action,The duration of action of orally administered GTN in the dog depended on the concentration used and was between 15 and 360 min.,[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),min,15 and 360,1924,DB00368,Norepinephrine
,3117068,half-life of elimination,"The half-life of elimination of G-2-N in the rat came to 2 h, and the substance was 100% bioavailable.",[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),h,2,1925,DB00368,Norepinephrine
≤,33125516,time to reach maximum plasma concentration,"Vericiguat (≤ 10.0 mg, IR tablets) was rapidly absorbed (median time to reach maximum plasma concentration ≤ 2.5 h [fasted]) with a mean half-life of about 22.0 h (range 17.9-27.0 h for single and multiple doses).","Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125516/),h,2.5,3456,DB00368,Norepinephrine
,33125516,half-life,"Vericiguat (≤ 10.0 mg, IR tablets) was rapidly absorbed (median time to reach maximum plasma concentration ≤ 2.5 h [fasted]) with a mean half-life of about 22.0 h (range 17.9-27.0 h for single and multiple doses).","Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125516/),h,22.0,3457,DB00368,Norepinephrine
,1381766,elimination half-life (t 1/2),"Synthetic ANF increased plasma ANF concentration by similar amounts, but the elimination half-life (t 1/2) for synthetic ANF was longer in the heart failure group (6.5 +/- 2.6 vs. 3.8 +/- 0.8 min, p less than 0.05).",Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1381766/),min,6.5,3691,DB00368,Norepinephrine
,1381766,elimination half-life (t 1/2),"Synthetic ANF increased plasma ANF concentration by similar amounts, but the elimination half-life (t 1/2) for synthetic ANF was longer in the heart failure group (6.5 +/- 2.6 vs. 3.8 +/- 0.8 min, p less than 0.05).",Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1381766/),min,3.8,3692,DB00368,Norepinephrine
,1381766,urinary sodium excretion,"Baseline urinary sodium excretion was less in the heart failure group (13.3 +/- 14.0 vs. 53.7 +/- 37.3 mumol/min, p less than 0.01) and ANF induced a smaller increase in urinary sodium excretion (22.1 +/- 32.3 mumol/min, p less than 0.05 vs. 305.7 +/- 242.9 mumol/min, p less than 0.001).",Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1381766/),[μM] / [min],13.3,3693,DB00368,Norepinephrine
,1381766,urinary sodium excretion,"Baseline urinary sodium excretion was less in the heart failure group (13.3 +/- 14.0 vs. 53.7 +/- 37.3 mumol/min, p less than 0.01) and ANF induced a smaller increase in urinary sodium excretion (22.1 +/- 32.3 mumol/min, p less than 0.05 vs. 305.7 +/- 242.9 mumol/min, p less than 0.001).",Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1381766/),[μM] / [min],53.7,3694,DB00368,Norepinephrine
,1381766,u,"Baseline urinary sodium excretion was less in the heart failure group (13.3 +/- 14.0 vs. 53.7 +/- 37.3 mumol/min, p less than 0.01) and ANF induced a smaller increase in urinary sodium excretion (22.1 +/- 32.3 mumol/min, p less than 0.05 vs. 305.7 +/- 242.9 mumol/min, p less than 0.001).",Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1381766/),mum,22.1,3695,DB00368,Norepinephrine
,7486614,volume of distribution,"CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours.",Clinical pharmacology of CNS 1102 in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486614/),[l] / [kg],6.2,6419,DB00368,Norepinephrine
,7486614,clearance,"CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours.",Clinical pharmacology of CNS 1102 in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486614/),[l] / [h],115,6420,DB00368,Norepinephrine
,7486614,plasma half-life,"CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours.",Clinical pharmacology of CNS 1102 in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486614/),h,4.5,6421,DB00368,Norepinephrine
,19571794,half-life,"Accordingly, to simulate the pharmacokinetic profile of a human METH binge exposure in rats, we used a computer-controlled, intravenous METH procedure (dynamic infusion, DI) to overcome species differences in METH pharmacokinetics and to replicate the human 12-h plasma METH half-life.",Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571794/),h,12,6679,DB00368,Norepinephrine
,18477074,cardiac index,"After aortic clamping, the cardiac index was higher [4(3.8-4.7) l/min/m(2) vs. 2.6(2.3-3.6) l/min/m(2); P<0.05] and the gastric mucosal-arterial pCO(2) gradient was lower in levosimendan-treated patients [0.9(0.6-1.2) kPa vs. 1.7(1.2-2.1) kPa; (P<0.05)].",Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477074/),[l·min] / [m(2],4,7506,DB00368,Norepinephrine
,18477074,cardiac index,"After aortic clamping, the cardiac index was higher [4(3.8-4.7) l/min/m(2) vs. 2.6(2.3-3.6) l/min/m(2); P<0.05] and the gastric mucosal-arterial pCO(2) gradient was lower in levosimendan-treated patients [0.9(0.6-1.2) kPa vs. 1.7(1.2-2.1) kPa; (P<0.05)].",Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477074/),[l·min] / [m(2],2.6,7507,DB00368,Norepinephrine
,18477074,pCO(2) gradient,"After aortic clamping, the cardiac index was higher [4(3.8-4.7) l/min/m(2) vs. 2.6(2.3-3.6) l/min/m(2); P<0.05] and the gastric mucosal-arterial pCO(2) gradient was lower in levosimendan-treated patients [0.9(0.6-1.2) kPa vs. 1.7(1.2-2.1) kPa; (P<0.05)].",Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477074/),kpa,0.9,7508,DB00368,Norepinephrine
,18477074,pCO(2) gradient,"After aortic clamping, the cardiac index was higher [4(3.8-4.7) l/min/m(2) vs. 2.6(2.3-3.6) l/min/m(2); P<0.05] and the gastric mucosal-arterial pCO(2) gradient was lower in levosimendan-treated patients [0.9(0.6-1.2) kPa vs. 1.7(1.2-2.1) kPa; (P<0.05)].",Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477074/),kpa,1.7,7509,DB00368,Norepinephrine
,18477074,total,"However, the total splanchnic blood flow, estimated by ICG-PDR, was comparable [29(21-29)% vs. 20(19-25)%; NS].",Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477074/),%,29,7510,DB00368,Norepinephrine
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,54,8991,DB00368,Norepinephrine
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,63,8992,DB00368,Norepinephrine
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,93,8993,DB00368,Norepinephrine
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,3,8994,DB00368,Norepinephrine
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,4,8995,DB00368,Norepinephrine
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,6,8996,DB00368,Norepinephrine
,8856481,plasma half-life (t1/2),Preliminary plasma half-life (t1/2) was calculated at 2 h.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,2,8997,DB00368,Norepinephrine
,6995479,steady-state plasma epinephrine concentrations,"These 30 infusions resulted in steady-state plasma epinephrine concentrations ranging from 24 to 1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[pg] / [ml],"24 to 1,020",9497,DB00368,Norepinephrine
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],52,9498,DB00368,Norepinephrine
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],89,9499,DB00368,Norepinephrine
,32500578,central volume of distribution,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),l,22.50,12708,DB00368,Norepinephrine
,32500578,peripheral volume of distribution,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),l,86.1,12709,DB00368,Norepinephrine
,32500578,systemic clearance,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),[l] / [h],34.7,12710,DB00368,Norepinephrine
,32500578,distribution clearance,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),[l] / [h],40.8,12711,DB00368,Norepinephrine
,2077146,half-life,"2) The blood concentration of captopril reached its peak in 2 h after medication, the mean value being 274 ng/ml and the half-life 3.16 h.",Effect of captopril on congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077146/),h,3.16,12750,DB00368,Norepinephrine
,8059340,Peak heart binding,Peak heart binding of [11C]cocaine was high (0.038-0.055%/g) and clearance was rapid (t1/2 from peak: 2.5-9 min) for both tracer doses and a pharmacological dose.,PET studies of cocaine inhibition of myocardial norepinephrine uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059340/),[%] / [g],0.038-0.055,16336,DB00368,Norepinephrine
,8059340,t1/2 from peak,Peak heart binding of [11C]cocaine was high (0.038-0.055%/g) and clearance was rapid (t1/2 from peak: 2.5-9 min) for both tracer doses and a pharmacological dose.,PET studies of cocaine inhibition of myocardial norepinephrine uptake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059340/),min,2.5-9,16337,DB00368,Norepinephrine
,20590604,K(i),"WAY-318068 is a potent and effective inhibitor of the NET with a K(i) of 8.7 nM in a binding assay, and an IC(50) of 6.8 nM in an assay of transporter function, without significant binding to the dopamine transporter.","WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590604/),nM,8.7,17447,DB00368,Norepinephrine
,20590604,IC(50),"WAY-318068 is a potent and effective inhibitor of the NET with a K(i) of 8.7 nM in a binding assay, and an IC(50) of 6.8 nM in an assay of transporter function, without significant binding to the dopamine transporter.","WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590604/),nM,6.8,17448,DB00368,Norepinephrine
,18840027,half-life of development,The half-life of development and regression of tolerance was estimated to be 30 minutes for the amplitude and 40 minutes for the recovery time.,Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840027/),min,30,21502,DB00368,Norepinephrine
less,2197816,oral bioavailability,Significant first-pass metabolism reduces oral bioavailability to less than 62 percent.,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),%,62,22476,DB00368,Norepinephrine
,2197816,volume of distribution,The drug is widely distributed throughout the body (volume of distribution 9-25 L/kg) and is 90-98 percent protein-bound.,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),[l] / [kg],9-25,22477,DB00368,Norepinephrine
,2197816,plasma half-life,"Clomipramine follows first-order elimination pharmacokinetics, with a plasma half-life of 20-24 hours.",Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),h,20-24,22478,DB00368,Norepinephrine
,9651106,constant flow rate,The liver was perfused with a recirculating system at a constant flow rate of 20 ml/min.,The pharmacokinetic change of lidocaine by catecholamines using isolated perfused rat liver (IPRL). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9651106/),[ml] / [min],20,22690,DB00368,Norepinephrine
,21034370,time to peak plasma concentration,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,2 - 4,26685,DB00368,Norepinephrine
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,18,26686,DB00368,Norepinephrine
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,33,26687,DB00368,Norepinephrine
,3325090,QT interval (QTc),4. The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),ms,334,28215,DB00368,Norepinephrine
,3325090,QT interval (QTc),4. The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),ms,302,28216,DB00368,Norepinephrine
,3325090,elimination half-life,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),h,13.4,28217,DB00368,Norepinephrine
,3325090,half-life,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),h,4.3,28218,DB00368,Norepinephrine
,3325090,AUC,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),[h·ng] / [ml],830,28219,DB00368,Norepinephrine
,3325090,AUC,5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC.,Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3325090/),[h·ng] / [ml],437,28220,DB00368,Norepinephrine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,379,29341,DB00368,Norepinephrine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,32.9,29342,DB00368,Norepinephrine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,37.2,29343,DB00368,Norepinephrine
,1686693,maximal plasma concentrations,200 mg ibopamine lead to maximal plasma concentrations of 60 to 100 nmol/l.,[Ibopamine--pharmacologic principles]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),[nM] / [l],60 to 100,29805,DB00368,Norepinephrine
,1686693,plasma half-life,The plasma half-life of epinine amounts to about 45 min.,[Ibopamine--pharmacologic principles]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),min,45,29806,DB00368,Norepinephrine
,1686693,affinity,"Investigations in isolated organs have shown that the action on DA1, DA2-receptors occurs in the range of 100-700 nmol/l), whereas stimulation of beta 1- and beta 2-receptors affords significantly higher levels (affinity to human cardiac beta 1- and beta 2-receptors 5-10 mumol/l).",[Ibopamine--pharmacologic principles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),[μM] / [l],5-10,29807,DB00368,Norepinephrine
,25069798,Cmax,"Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121.83 ng/mL [90% CI, 111.80-132.75]).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],121.83,30557,DB00368,Norepinephrine
,25069798,AUC0-τ,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],98.71,30558,DB00368,Norepinephrine
,25069798,Cmax,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],101.44,30559,DB00368,Norepinephrine
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],96.54,30560,DB00368,Norepinephrine
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],106.39,30561,DB00368,Norepinephrine
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],89.67,30562,DB00368,Norepinephrine
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],106.32,30563,DB00368,Norepinephrine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],39.8,32819,DB00368,Norepinephrine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],28.3,32820,DB00368,Norepinephrine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],32.6,32821,DB00368,Norepinephrine
,9350366,half-life,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),min,14,32822,DB00368,Norepinephrine
,9350366,clearance,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[l] / [min],2.1,32823,DB00368,Norepinephrine
,15318058,total plasma epinephrine,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],323,35078,DB00368,Norepinephrine
,15318058,total plasma epinephrine,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],24.8,35079,DB00368,Norepinephrine
,15318058,peak,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],323,35080,DB00368,Norepinephrine
,15318058,peak,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],24.8,35081,DB00368,Norepinephrine
,15318058,time to peak,Estimated time to peak exogenous epinephrine level ranged from 1 to 4 hours from the start of infiltration.,Pharmacokinetics and safety of epinephrine use in liposuction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),h,1 to 4,35082,DB00368,Norepinephrine
,15318058,Area under the plasma concentration versus time curve,Area under the plasma concentration versus time curve was approximately 2089 to 2610 pg x hour/ml.,Pharmacokinetics and safety of epinephrine use in liposuction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[h·pg] / [ml],2089 to 2610,35083,DB00368,Norepinephrine
,15318058,Peak exogenous epinephrine concentration,Peak exogenous epinephrine concentration was estimated to be 286 to 335 pg/ml.,Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],286 to 335,35084,DB00368,Norepinephrine
,15318058,Clearance,"Clearance was 764,508 ml/hour and volume of distribution was 0.4 liter/kg (0.006 liter/kg).",Pharmacokinetics and safety of epinephrine use in liposuction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[ml] / [h],"764,508",35085,DB00368,Norepinephrine
,15318058,volume of distribution,"Clearance was 764,508 ml/hour and volume of distribution was 0.4 liter/kg (0.006 liter/kg).",Pharmacokinetics and safety of epinephrine use in liposuction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[l] / [kg],0.4,35086,DB00368,Norepinephrine
,15509185,bioavailability,"Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules.",Clinical pharmacology of tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,87-95,35613,DB00368,Norepinephrine
,15509185,plasma protein binding,Tramadol is rapidly distributed in the body; plasma protein binding is about 20%.,Clinical pharmacology of tramadol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,20,35614,DB00368,Norepinephrine
,15509185,elimination half-life,The mean elimination half-life is about 6 hours.,Clinical pharmacology of tramadol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),h,6,35615,DB00368,Norepinephrine
,4014356,initial half-life,"In both, the dopamine clearance was biphasic with an initial half-life of 1.5 minutes in fetal blood and 1.0 minute in maternal blood.",3H-dopamine clearance from the intravascular compartment of the maternal and fetal rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014356/),min,1.5,38925,DB00368,Norepinephrine
,4014356,initial half-life,"In both, the dopamine clearance was biphasic with an initial half-life of 1.5 minutes in fetal blood and 1.0 minute in maternal blood.",3H-dopamine clearance from the intravascular compartment of the maternal and fetal rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014356/),min,1.0,38926,DB00368,Norepinephrine
,26798023,apparent oral clearance,"The population estimates of apparent oral clearance and apparent central volume of distribution were 257 L/h and 1870 L, respectively.",Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26798023/),[l] / [h],257,42196,DB00368,Norepinephrine
,26798023,apparent central volume of distribution,"The population estimates of apparent oral clearance and apparent central volume of distribution were 257 L/h and 1870 L, respectively.",Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26798023/),l,1870,42197,DB00368,Norepinephrine
,3595699,terminal half-life,"Ketanserin had a terminal half-life of 29.2 h, a plasma clearance of 518 ml/min and a volume of distribution of 18.0 l/kg.",Pharmacokinetics of ketanserin in patients with essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),h,29.2,45687,DB00368,Norepinephrine
,3595699,plasma clearance,"Ketanserin had a terminal half-life of 29.2 h, a plasma clearance of 518 ml/min and a volume of distribution of 18.0 l/kg.",Pharmacokinetics of ketanserin in patients with essential hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),[ml] / [min],518,45688,DB00368,Norepinephrine
,3595699,volume of distribution,"Ketanserin had a terminal half-life of 29.2 h, a plasma clearance of 518 ml/min and a volume of distribution of 18.0 l/kg.",Pharmacokinetics of ketanserin in patients with essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),[l] / [kg],18.0,45689,DB00368,Norepinephrine
,3595699,peak concentration,Chronic oral intake of 40 mg ketanserin (tablet formulation) gave a peak concentration of unchanged ketanserin of 88 ng/ml after 1.1 h.,Pharmacokinetics of ketanserin in patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),[ng] / [ml],88,45690,DB00368,Norepinephrine
,3595699,absolute bioavailability,Its absolute bioavailability was 48%.,Pharmacokinetics of ketanserin in patients with essential hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),%,48,45691,DB00368,Norepinephrine
,3595699,maximal concentration,During chronic therapy the maximal concentration of ketanserin-ol was 208 ng/ml and its half-life of elimination was 35.0 h.,Pharmacokinetics of ketanserin in patients with essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),[ng] / [ml],208,45692,DB00368,Norepinephrine
,3595699,half-life of elimination,During chronic therapy the maximal concentration of ketanserin-ol was 208 ng/ml and its half-life of elimination was 35.0 h.,Pharmacokinetics of ketanserin in patients with essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595699/),h,35.0,45693,DB00368,Norepinephrine
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],3.9,47136,DB00368,Norepinephrine
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],0.7,47137,DB00368,Norepinephrine
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],51.5,47138,DB00368,Norepinephrine
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],9.4,47139,DB00368,Norepinephrine
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47140,DB00368,Norepinephrine
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47141,DB00368,Norepinephrine
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],6.0,47142,DB00368,Norepinephrine
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47143,DB00368,Norepinephrine
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],38.8,47144,DB00368,Norepinephrine
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47145,DB00368,Norepinephrine
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),pm,2.86,47146,DB00368,Norepinephrine
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[pM] / [ml],4.80,47147,DB00368,Norepinephrine
,9349926,Initial pain intensity,"Initial pain intensity was 5.9 (arbitrary units) and 5.4 in the groups with and without signs of transmural myocardial damage, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),,5.9,48512,DB00368,Norepinephrine
,9349926,Initial pain intensity,"Initial pain intensity was 5.9 (arbitrary units) and 5.4 in the groups with and without signs of transmural myocardial damage, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),,5.4,48513,DB00368,Norepinephrine
,9349926,terminal half-life,The terminal half-life of unchanged metoprolol ranged from 2.5 to 8.5 h in group 1 and from 2.2 to 5.2 h in group 2.,Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,2.5 to 8.5,48514,DB00368,Norepinephrine
,9349926,terminal half-life,The terminal half-life of unchanged metoprolol ranged from 2.5 to 8.5 h in group 1 and from 2.2 to 5.2 h in group 2.,Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,2.2 to 5.2,48515,DB00368,Norepinephrine
,9349926,half-life,"In group 1, metoprolol half-life was 4.5 h and total plasma clearance (CL) 54.1 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,4.5,48516,DB00368,Norepinephrine
,9349926,total plasma clearance (CL),"In group 1, metoprolol half-life was 4.5 h and total plasma clearance (CL) 54.1 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),[1] / [h],54.1,48517,DB00368,Norepinephrine
,9349926,half-life,"In group 2, the metoprolol half-life was 3.7 h and total plasma clearance 75.4 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,3.7,48518,DB00368,Norepinephrine
,9349926,total plasma clearance,"In group 2, the metoprolol half-life was 3.7 h and total plasma clearance 75.4 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),[1] / [h],75.4,48519,DB00368,Norepinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,143,48520,DB00368,Norepinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,135,48521,DB00368,Norepinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,2830,48522,DB00368,Norepinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,1653,48523,DB00368,Norepinephrine
,33324051,bioavailability,Duloxetine (DLX) is dual serotonin and norepinephrine reuptake inhibitor suffering from limited bioavailability (≈ 40%) due to extensive hepatic metabolism.,"Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),%,40,50571,DB00368,Norepinephrine
,33324051,PS,"It had PS of 265.13 ± 9.85 nm, GT of 32 ± 0.05°C, EE% of 98.13 ± 0.50%, and showed controlled release behavior where 33% DLX was released within 6 hrs.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),nm,265.13,50572,DB00368,Norepinephrine
,33324051,GT,"It had PS of 265.13 ± 9.85 nm, GT of 32 ± 0.05°C, EE% of 98.13 ± 0.50%, and showed controlled release behavior where 33% DLX was released within 6 hrs.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),°,32,50573,DB00368,Norepinephrine
,33324051,EE%,"It had PS of 265.13 ± 9.85 nm, GT of 32 ± 0.05°C, EE% of 98.13 ± 0.50%, and showed controlled release behavior where 33% DLX was released within 6 hrs.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),%,98.13,50574,DB00368,Norepinephrine
,33324051,BTE%,"Its BTE% and DTP% were 137.77 and 10.5, respectively, indicating efficient brain targeting after intranasal administration.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),,137.77,50575,DB00368,Norepinephrine
,33324051,DTP%,"Its BTE% and DTP% were 137.77 and 10.5, respectively, indicating efficient brain targeting after intranasal administration.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),,10.5,50576,DB00368,Norepinephrine
,7721229,elimination half-life time (t1/2,"Kinetics of amitriptyline (AMI), its demethylated metabolites nortriptyline (NOR) and demethylnortriptyline (DM-NOR), and its hydroxylated metabolites, the E and Z isomers or 10-hydroxy-amitriptyline (E- and Z-10-OH-AMI) and of 10-hydroxynortriptyline (E- and Z-10-OH-NOR) were studied in plasma and brain from Swiss CD1 mice after six successive intraperitoneal injections of amitriptyline (10 mg/kg) administered every elimination half-life time (t1/2 = 3.1 h) to obtain the steady state.",Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half-life repeated administration. Comparison with acute administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721229/),h,3.1,50913,DB00368,Norepinephrine
,26796604,maximum blood,"2. Mean (± SD) maximum blood and plasma radioactivity concentrations were 359 ± 34.2 and 638 ± 64.7 ngEq free base/g, respectively, at 2 h post-dose.","Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26796604/),[base·free·ngeq] / [g],359,53742,DB00368,Norepinephrine
,26796604,plasma radioactivity concentrations,"2. Mean (± SD) maximum blood and plasma radioactivity concentrations were 359 ± 34.2 and 638 ± 64.7 ngEq free base/g, respectively, at 2 h post-dose.","Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26796604/),[base·free·ngeq] / [g],638,53743,DB00368,Norepinephrine
,10839469,total urinary recovery,Mean total urinary recovery ranged from 4.06 to 6.17%.,Pharmacokinetics of reboxetine in elderly patients with depressive disorders. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839469/),%,4.06 to 6.17,54674,DB00368,Norepinephrine
,10839469,AUCtau,"The mean area under the plasma concentration-time curve (AUCtau) and the maximum plasma drug concentration (Cmax) showed considerable variation between patients; at a dosage of 4 mg/day, AUCtau was 1,466-6,866 ngxh/ml and Cmax ranged from 169 to 663 ng/ml.",Pharmacokinetics of reboxetine in elderly patients with depressive disorders. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839469/),[h·ng] / [ml],"1,466-6,866",54675,DB00368,Norepinephrine
,10839469,Cmax,"The mean area under the plasma concentration-time curve (AUCtau) and the maximum plasma drug concentration (Cmax) showed considerable variation between patients; at a dosage of 4 mg/day, AUCtau was 1,466-6,866 ngxh/ml and Cmax ranged from 169 to 663 ng/ml.",Pharmacokinetics of reboxetine in elderly patients with depressive disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839469/),[ng] / [ml],169 to 663,54676,DB00368,Norepinephrine
,29016875,occupancy,"Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg.","Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016875/),%,29.7,55445,DB00368,Norepinephrine
,29016875,occupancy,"Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg.","Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016875/),%,30.5,55446,DB00368,Norepinephrine
,29016875,occupancy,"Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg.","Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016875/),%,40.0,55447,DB00368,Norepinephrine
,25522383,plasma EC50,"TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7 ng/mL and 50.8 ng/mL, respectively, consistent with modest selectivity for NET in vivo.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],11.7,55633,DB00368,Norepinephrine
,25522383,plasma EC50,"TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7 ng/mL and 50.8 ng/mL, respectively, consistent with modest selectivity for NET in vivo.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],50.8,55634,DB00368,Norepinephrine
,25522383,plasma EC50,"Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5 ng/mL and 23.9 ng/mL, respectively.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],5.5,55635,DB00368,Norepinephrine
,25522383,plasma EC50,"Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5 ng/mL and 23.9 ng/mL, respectively.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],23.9,55636,DB00368,Norepinephrine
,25522383,half-life,The long pharmacokinetic half-life (30-40 h) of TD-9855 allowed for sequential assessment of SERT and NET occupancy in the same subject.,"Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),h,30-40,55637,DB00368,Norepinephrine
,25522383,plasma EC50,"The plasma EC50 for NET was estimated to be 1.21 ng/mL, and at doses of greater than 4 mg the projected steady-state NET occupancy is high (>75%).","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],1.21,55638,DB00368,Norepinephrine
,25522383,occupancy,"After a single oral dose of 20mg, SERT occupancy was 25 (±8)% at a plasma level of 6.35 ng/mL.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),%,25,55639,DB00368,Norepinephrine
,19722525,IC(50),"Numerous compounds (e.g., 19-22) had low nonamolar hNET potency with IC(50) values of 7-10 nM and excellent selectivity (>500 fold) at hNET over hSERT and hDAT.","1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19722525/),nM,7-10,56724,DB00368,Norepinephrine
,7586944,area under the concentration-time curve,Values for area under the concentration-time curve for atipamezole (mean +/- SD) ranged from 26 +/- 4 ng x hr/ml after 5 mg to 112 +/- 21 ng x hr/ml after 40 mg and peak concentrations ranged from 11 +/- 3 ng/ml after 5 mg to 38 +/- 9 ng/ml after 40 mg.,"Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),[h·ng] / [ml],26,58102,DB00368,Norepinephrine
,7586944,area under the concentration-time curve,Values for area under the concentration-time curve for atipamezole (mean +/- SD) ranged from 26 +/- 4 ng x hr/ml after 5 mg to 112 +/- 21 ng x hr/ml after 40 mg and peak concentrations ranged from 11 +/- 3 ng/ml after 5 mg to 38 +/- 9 ng/ml after 40 mg.,"Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),[h·ng] / [ml],112,58103,DB00368,Norepinephrine
,7586944,peak concentrations,Values for area under the concentration-time curve for atipamezole (mean +/- SD) ranged from 26 +/- 4 ng x hr/ml after 5 mg to 112 +/- 21 ng x hr/ml after 40 mg and peak concentrations ranged from 11 +/- 3 ng/ml after 5 mg to 38 +/- 9 ng/ml after 40 mg.,"Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),[ng] / [ml],11,58104,DB00368,Norepinephrine
,7586944,peak concentrations,Values for area under the concentration-time curve for atipamezole (mean +/- SD) ranged from 26 +/- 4 ng x hr/ml after 5 mg to 112 +/- 21 ng x hr/ml after 40 mg and peak concentrations ranged from 11 +/- 3 ng/ml after 5 mg to 38 +/- 9 ng/ml after 40 mg.,"Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),[ng] / [ml],38,58105,DB00368,Norepinephrine
,7586944,elimination half-lives,Mean elimination half-lives were approximately 1 1/2 hours after every treatment.,"Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),h,1 1/2,58106,DB00368,Norepinephrine
,7586944,bioavailability,"In part two, a mean bioavailability of 33% was calculated for buccal administration (compared with intravenous), whereas systemic availability after an oral dose was < 2%.","Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),%,33,58107,DB00368,Norepinephrine
<,7586944,systemic availability,"In part two, a mean bioavailability of 33% was calculated for buccal administration (compared with intravenous), whereas systemic availability after an oral dose was < 2%.","Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),%,2,58108,DB00368,Norepinephrine
,7586944,total clearance,"After intravenous administration the mean total clearance, apparent volume of distribution, and elimination half-life were 1.2 L/hr/kg, 2.9 L/kg, and 1.8 hours, respectively.","Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),[l] / [h·kg],1.2,58109,DB00368,Norepinephrine
,7586944,apparent volume of distribution,"After intravenous administration the mean total clearance, apparent volume of distribution, and elimination half-life were 1.2 L/hr/kg, 2.9 L/kg, and 1.8 hours, respectively.","Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),[l] / [kg],2.9,58110,DB00368,Norepinephrine
,7586944,elimination half-life,"After intravenous administration the mean total clearance, apparent volume of distribution, and elimination half-life were 1.2 L/hr/kg, 2.9 L/kg, and 1.8 hours, respectively.","Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586944/),h,1.8,58111,DB00368,Norepinephrine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,21.5,59195,DB00368,Norepinephrine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,18.9,59196,DB00368,Norepinephrine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.8,59197,DB00368,Norepinephrine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.4,59198,DB00368,Norepinephrine
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.76,59199,DB00368,Norepinephrine
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.39,59200,DB00368,Norepinephrine
,2142031,plasma half-life,"The plasma half-life was 10.0 +/- 2.6 min, significantly longer than that reported previously in normal dogs.","Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142031/),min,10.0,60750,DB00368,Norepinephrine
,8878056,half-lives for elimination,"The pharmacokinetics of decynium22 and disprocynium24 were similar; they were characterized by short half-lives for elimination (8.2 and 4.5 min, respectively) and very high plasma clearances (173 and 180 ml kg-1 min-1, respectively).",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),min,8.2,60807,DB00368,Norepinephrine
,8878056,half-lives for elimination,"The pharmacokinetics of decynium22 and disprocynium24 were similar; they were characterized by short half-lives for elimination (8.2 and 4.5 min, respectively) and very high plasma clearances (173 and 180 ml kg-1 min-1, respectively).",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),min,4.5,60808,DB00368,Norepinephrine
,8878056,plasma clearances,"The pharmacokinetics of decynium22 and disprocynium24 were similar; they were characterized by short half-lives for elimination (8.2 and 4.5 min, respectively) and very high plasma clearances (173 and 180 ml kg-1 min-1, respectively).",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),[ml] / [kg·min],173,60809,DB00368,Norepinephrine
,8878056,plasma clearances,"The pharmacokinetics of decynium22 and disprocynium24 were similar; they were characterized by short half-lives for elimination (8.2 and 4.5 min, respectively) and very high plasma clearances (173 and 180 ml kg-1 min-1, respectively).",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),[ml] / [kg·min],180,60810,DB00368,Norepinephrine
,8878056,pA2,"Decynium22 antagonized the noradrenaline-induced contraction; the pA2 for this interaction was 7.6, and the slope of the corresponding Schild plot was unity.",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),,7.6,60811,DB00368,Norepinephrine
,8878056,Ki's,"The Ki's were 5.3 and 240 mumol l-1 for decynium22 and disprocynium24, respectively.",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),[μM] / [l],5.3,60812,DB00368,Norepinephrine
,8878056,Ki's,"The Ki's were 5.3 and 240 mumol l-1 for decynium22 and disprocynium24, respectively.",Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878056/),[μM] / [l],240,60813,DB00368,Norepinephrine
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8878,61872,DB00368,Norepinephrine
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8414,61873,DB00368,Norepinephrine
,12072587,Tmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),min,5,61874,DB00368,Norepinephrine
,12072587,Cmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),[pg] / [ml],715,61875,DB00368,Norepinephrine
,12072587,half-life,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),h,11.4,61876,DB00368,Norepinephrine
,15740795,K(i),"BMS-505130 is a potent and selective serotonin transport inhibitor; K(i) for binding to the serotonin transporter = 0.18 nM (K(i) values for binding to the norepinephrine and dopamine transporters = 4.6 and 2.1 microM, respectively).","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),nM,0.18,63515,DB00368,Norepinephrine
,15740795,K(i),"BMS-505130 is a potent and selective serotonin transport inhibitor; K(i) for binding to the serotonin transporter = 0.18 nM (K(i) values for binding to the norepinephrine and dopamine transporters = 4.6 and 2.1 microM, respectively).","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),μM,4.6,63516,DB00368,Norepinephrine
,15740795,K(i),"BMS-505130 is a potent and selective serotonin transport inhibitor; K(i) for binding to the serotonin transporter = 0.18 nM (K(i) values for binding to the norepinephrine and dopamine transporters = 4.6 and 2.1 microM, respectively).","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),μM,2.1,63517,DB00368,Norepinephrine
,15740795,plasma half-life,"Following oral administration, peak plasma concentrations of BMS-505130 reached Tmax at 1.6 +/- 0.7 h and then declined to concentrations <10% of Cmax within the following 6 h; plasma half-life following i.v. dosing was 0.46 +/- 0.02 h.","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),h,0.46,63518,DB00368,Norepinephrine
,3158689,cardiac output,"MDL 17,043 acutely increased cardiac output from 3.6 +/- 0.9 to 4.6 +/- 1.0 liters/min (+28%, p less than 0.001) and decreased mean pulmonary artery wedge pressure from 24 +/- 8 to 13 +/- 8 mm Hg (-46%, p less than 0.001), mean right atrial pressure from 10 +/- 5 to 4 +/- 4 mm Hg (-60%, p less than 0.001) and mean arterial pressure from 78 +/- 9 to 70 +/- 11 mm Hg (-10%, p less than 0.001).","MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158689/),[l] / [min],3.6,64138,DB00368,Norepinephrine
,3158689,cardiac output,"MDL 17,043 acutely increased cardiac output from 3.6 +/- 0.9 to 4.6 +/- 1.0 liters/min (+28%, p less than 0.001) and decreased mean pulmonary artery wedge pressure from 24 +/- 8 to 13 +/- 8 mm Hg (-46%, p less than 0.001), mean right atrial pressure from 10 +/- 5 to 4 +/- 4 mm Hg (-60%, p less than 0.001) and mean arterial pressure from 78 +/- 9 to 70 +/- 11 mm Hg (-10%, p less than 0.001).","MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158689/),[l] / [min],4.6,64139,DB00368,Norepinephrine
,3158689,Elimination half-life,"Elimination half-life for MDL 17,043 was approximately 20 hours.","MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158689/),h,20,64140,DB00368,Norepinephrine
,11669473,Kd,Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),nM,3.2,65070,DB00368,Norepinephrine
,11669473,K(on),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[M·min],2.8 x 10(7),65071,DB00368,Norepinephrine
,11669473,K(off),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[min],0.099,65072,DB00368,Norepinephrine
,11669473,Kd,Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),nM,1.5,65073,DB00368,Norepinephrine
,11669473,Kd,Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),nM,1.35,65074,DB00368,Norepinephrine
,11669473,K(on),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[M·min],2 x 10(7),65075,DB00368,Norepinephrine
,11669473,K(off),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[min],0.069,65076,DB00368,Norepinephrine
,27807818,peak plasma concentration (C max)/minimal inhibitory concentration (MIC) ratio,The therapeutic effect of aminoglycosides is highest and optimal when the peak plasma concentration (C max)/minimal inhibitory concentration (MIC) ratio is between 8 and 10.,Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),,8 and 10,66302,DB00368,Norepinephrine
,27807818,C max,"In clinical practice, the recommended target is an amikacin C max between 60 and 80 mg/L, which corresponds to approximately 8 times the MIC breakpoint, as defined by the European Committee on Antimicrobial Susceptibility Testing.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60 and 80,66303,DB00368,Norepinephrine
,27807818,C max,"The target C max for amikacin was between 60 and 80 mg/L, as recommended by French guidelines (i.e. C max/MIC breakpoint = 8-10).",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60 and 80,66304,DB00368,Norepinephrine
,27807818,C max/MIC,"The target C max for amikacin was between 60 and 80 mg/L, as recommended by French guidelines (i.e. C max/MIC breakpoint = 8-10).",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),,8-10,66305,DB00368,Norepinephrine
<,27807818,C max,"Over the study period, the amikacin C max was <60 mg/L, between 60 and 80 mg/L, and >80 mg/L in 20 (18.2%), 46 (41.8%) and 44 (40%) of the 110 selected patients, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60,66306,DB00368,Norepinephrine
,27807818,C max,"Over the study period, the amikacin C max was <60 mg/L, between 60 and 80 mg/L, and >80 mg/L in 20 (18.2%), 46 (41.8%) and 44 (40%) of the 110 selected patients, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60 and 80,66307,DB00368,Norepinephrine
>,27807818,C max,"Over the study period, the amikacin C max was <60 mg/L, between 60 and 80 mg/L, and >80 mg/L in 20 (18.2%), 46 (41.8%) and 44 (40%) of the 110 selected patients, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],80,66308,DB00368,Norepinephrine
,27807818,Mortality rate,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),%,40,66309,DB00368,Norepinephrine
,27807818,Mortality rate,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),%,28,66310,DB00368,Norepinephrine
,27807818,Mortality rate,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),%,56,66311,DB00368,Norepinephrine
<,27807818,Mortality rate,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60,66312,DB00368,Norepinephrine
<,27807818,C max,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60,66313,DB00368,Norepinephrine
<,27807818,C max,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],80,66314,DB00368,Norepinephrine
>,27807818,C max,"Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C max < 60 mg/L, 60 mg/L < C max < 80 mg/L and C max > 80 mg/L, respectively.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],80,66315,DB00368,Norepinephrine
between,27807818,C max,"Following multivariate analysis, mortality rate was significantly lower in the group of patients with amikacin C max between 60 and 80 mg/L than in the group of patients with amikacin C max > 80 mg/L (P = 0.004).",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60 and 80,66316,DB00368,Norepinephrine
>,27807818,C max,"Following multivariate analysis, mortality rate was significantly lower in the group of patients with amikacin C max between 60 and 80 mg/L than in the group of patients with amikacin C max > 80 mg/L (P = 0.004).",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],80,66317,DB00368,Norepinephrine
<,27807818,C max,"With a loading dose of 30 mg/kg of amikacin, concentration was potentially suboptimal (C max < 60 mg/L) in only 18.2% of patients.",Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],60,66318,DB00368,Norepinephrine
<,27807818,C max,The pharmacodynamic target (60 mg/L < C max < 80 mg/L) recommended by French guidelines was reached in 41.8% of patients and was associated with reduced in-ICU mortality.,Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],80,66319,DB00368,Norepinephrine
>,27807818,C max,But amikacin overexposure (i.e. C max > 80 mg/L) was frequent and potentially associated with increased mortality.,Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27807818/),[mg] / [l],80,66320,DB00368,Norepinephrine
,34062113,elimination half-life (t1/2),PK values in control rats showed dose-dependent increases in maximum serum concentrations (Cmax) and area under the curve (AUCinf) values with an elimination half-life (t1/2) of approximately 2.1 h.,Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34062113/),h,2.1,66826,DB00368,Norepinephrine
,8474536,plasma half-life,"More than 150 min of COMT inhibition were required for endogenous MOPEG to disappear from plasma, since the plasma half-life of MOPEG was 54 min.","The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474536/),min,54,68127,DB00368,Norepinephrine
,8474536,plasma half-life,"The results concerning the effect of COMT inhibition on the plasma kinetics of infused DOPA and DOPEG were as follows: the plasma clearance of DOPA was not altered, whereas that of DOPEG fell by 41%; the plasma half-life of DOPA increased from 4.9 to 13.0 min and that of DOPEG from 4.8 to 31.0 min; there was an increase in the volume of distribution of DOPA (2 to 3-fold) and DOPEG (4 to 5-fold).","The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474536/),min,4.9 to 13.0,68128,DB00368,Norepinephrine
,8474536,plasma half-life,"The results concerning the effect of COMT inhibition on the plasma kinetics of infused DOPA and DOPEG were as follows: the plasma clearance of DOPA was not altered, whereas that of DOPEG fell by 41%; the plasma half-life of DOPA increased from 4.9 to 13.0 min and that of DOPEG from 4.8 to 31.0 min; there was an increase in the volume of distribution of DOPA (2 to 3-fold) and DOPEG (4 to 5-fold).","The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474536/),min,4.8 to 31.0,68129,DB00368,Norepinephrine
,282106,metabolic clearance rate,"2. The metabolic clearance rate of plasma noradrenaline in normal subjects was approximately 1 1 min-1 m-2, whereas in essential hypertensive patients it was significantly reduced to approximately 0.6 1 min-1 m-2.",The kinetics of plasma noradrenaline in normal and hypertensive subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282106/),[1] / [(m)^2·min],1,68764,DB00368,Norepinephrine
,282106,metabolic clearance rate,"2. The metabolic clearance rate of plasma noradrenaline in normal subjects was approximately 1 1 min-1 m-2, whereas in essential hypertensive patients it was significantly reduced to approximately 0.6 1 min-1 m-2.",The kinetics of plasma noradrenaline in normal and hypertensive subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282106/),[1] / [(m)^2·min],0.6,68765,DB00368,Norepinephrine
,17419605,uptake rates,"In isolated rat hearts, neuronal uptake rates of [11C]1a-m ranged from 0.24 to 1.96 mL min-1 (g wet wt)-1, and six compounds had extremely long neuronal retention times (clearance T1/2 > 20 h) due to efficient vesicular storage.",Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17419605/),[g·ml] / [min],0.24 to 1.96,69967,DB00368,Norepinephrine
>,17419605,clearance T1/2,"In isolated rat hearts, neuronal uptake rates of [11C]1a-m ranged from 0.24 to 1.96 mL min-1 (g wet wt)-1, and six compounds had extremely long neuronal retention times (clearance T1/2 > 20 h) due to efficient vesicular storage.",Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17419605/),h,20,69968,DB00368,Norepinephrine
,3100310,pulmonary arterial-systemic arterial extraction ratio,"The pulmonary arterial-systemic arterial extraction ratio of NA was mean 0.08 (n = 9) as compared to that of 3H-NA: mean 0.07 (n = 8, NS).",Pulmonary extraction of circulating noradrenaline in man. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),,0.08,70990,DB00368,Norepinephrine
,3100310,pulmonary arterial-systemic arterial extraction ratio,"The pulmonary arterial-systemic arterial extraction ratio of NA was mean 0.08 (n = 9) as compared to that of 3H-NA: mean 0.07 (n = 8, NS).",Pulmonary extraction of circulating noradrenaline in man. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),,0.07,70991,DB00368,Norepinephrine
,3100310,pulmonary clearances,"Likewise mean pulmonary clearances of NA and 3H-NA were not significantly different (97 ml min-1 X M-2 v. 124 ml min-1 X M-2, NS).",Pulmonary extraction of circulating noradrenaline in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),[ml] / [(M)^2·min],97,70992,DB00368,Norepinephrine
,3100310,pulmonary clearances,"Likewise mean pulmonary clearances of NA and 3H-NA were not significantly different (97 ml min-1 X M-2 v. 124 ml min-1 X M-2, NS).",Pulmonary extraction of circulating noradrenaline in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),[ml] / [(M)^2·min],124,70993,DB00368,Norepinephrine
,3100310,whole-body clearance,Estimated whole-body clearance of noradrenaline was mean 0.80 l min-1 X M-2 (n = 6) while the pulmonary clearance amounted to 19% of this value.,Pulmonary extraction of circulating noradrenaline in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),[l] / [(M)^2·min],0.80,70994,DB00368,Norepinephrine
,10761166,AUC0-24,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),[min·μg] / [ml],95,72570,DB00368,Norepinephrine
,10761166,AUC0-24,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),min,172.5,72571,DB00368,Norepinephrine
,10761166,t1/2,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),[min·μg] / [ml],176,72572,DB00368,Norepinephrine
,10761166,t1/2,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),min,628,72573,DB00368,Norepinephrine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,85.8,73658,DB00368,Norepinephrine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,80.0,73659,DB00368,Norepinephrine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,66.4,73660,DB00368,Norepinephrine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,57.1,73661,DB00368,Norepinephrine
>,30865315,half-life,"Geometric mean area under the plasma concentration-time curve from time zero to time of last quantifiable concentration increased 357% and 518% vs normal in ESRD with and without hemodialysis, respectively, with half-life >100 hours in both groups.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),h,100,73662,DB00368,Norepinephrine
,7699942,Cmax,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),[ng] / [ml],59.1,77484,DB00368,Norepinephrine
,7699942,AUC,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),[h·ng] / [ml],288.2,77485,DB00368,Norepinephrine
,7699942,Tmax,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),h,3.4,77486,DB00368,Norepinephrine
,7699942,t1/2,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),h,5.5,77487,DB00368,Norepinephrine
,1617029,Maximum venous,"Maximum venous (642 +/- 182 ng/ml after 3.5 +/- 0.3 min) and arterial (147 +/- 21 ng/ml after 4.2 +/- 0.4 min) NE concentrations in group A were significantly higher compared with values in group B (77 +/- 18 ng/ml after 5.5 +/- 0.5 min venous, 46 +/- 11 ng/ml after 6.0 +/- 0.7 min arterial).",[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [ml],642,83883,DB00368,Norepinephrine
,1617029,Maximum venous,"Maximum venous (642 +/- 182 ng/ml after 3.5 +/- 0.3 min) and arterial (147 +/- 21 ng/ml after 4.2 +/- 0.4 min) NE concentrations in group A were significantly higher compared with values in group B (77 +/- 18 ng/ml after 5.5 +/- 0.5 min venous, 46 +/- 11 ng/ml after 6.0 +/- 0.7 min arterial).",[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [ml],147,83884,DB00368,Norepinephrine
,1617029,Maximum venous,"Maximum venous (642 +/- 182 ng/ml after 3.5 +/- 0.3 min) and arterial (147 +/- 21 ng/ml after 4.2 +/- 0.4 min) NE concentrations in group A were significantly higher compared with values in group B (77 +/- 18 ng/ml after 5.5 +/- 0.5 min venous, 46 +/- 11 ng/ml after 6.0 +/- 0.7 min arterial).",[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [ml],77,83885,DB00368,Norepinephrine
,1617029,area under the curve (AUC),The area under the curve (AUC) in group A was calculated to be 55 +/- 12 ng/ml min (venous) and 35 +/- 7 ng/ml min (arterial) representing a pulmonary first-pass effect of 40%.,[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [min·ml],55,83886,DB00368,Norepinephrine
,1617029,area under the curve (AUC),The area under the curve (AUC) in group A was calculated to be 55 +/- 12 ng/ml min (venous) and 35 +/- 7 ng/ml min (arterial) representing a pulmonary first-pass effect of 40%.,[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [min·ml],35,83887,DB00368,Norepinephrine
,1617029,AUC,"In group B, the dose-adjusted AUC (39 +/- 13 ng/ml min venous, 30 +/- 10 ng/ml min arterial) represented a pulmonary first-pass effect of only 25%.",[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [min·ml],39,83888,DB00368,Norepinephrine
,1617029,AUC,"In group B, the dose-adjusted AUC (39 +/- 13 ng/ml min venous, 30 +/- 10 ng/ml min arterial) represented a pulmonary first-pass effect of only 25%.",[The pulmonary first pass effect of noradrenaline following intravenous and endobronchial administration for resuscitation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617029/),[ng] / [min·ml],30,83889,DB00368,Norepinephrine
,29534338,peak,Measured metformin concentrations were extremely high with a peak of 292 μg ml-1 at 8 h postingestion.,'Massive' metformin overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),[μg] / [ml],292,86082,DB00368,Norepinephrine
,29534338,apparent oral clearance,Pharmacokinetic analysis of metformin concentrations found a reduced apparent oral clearance of 8.2 l h-1 and a half-life of approximately 30 h.,'Massive' metformin overdose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),[l] / [h],8.2,86083,DB00368,Norepinephrine
,29534338,half-life,Pharmacokinetic analysis of metformin concentrations found a reduced apparent oral clearance of 8.2 l h-1 and a half-life of approximately 30 h.,'Massive' metformin overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),h,30,86084,DB00368,Norepinephrine
,29534338,apparent oral clearance,"During IHD, the apparent oral clearance increased to 22.2 l h-1 with an approximate half-life of 10 h.",'Massive' metformin overdose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),[l] / [h],22.2,86085,DB00368,Norepinephrine
,29534338,half-life,"During IHD, the apparent oral clearance increased to 22.2 l h-1 with an approximate half-life of 10 h.",'Massive' metformin overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29534338/),h,10,86086,DB00368,Norepinephrine
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB00368,Norepinephrine
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB00368,Norepinephrine
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB00368,Norepinephrine
,17765221,K(i),"JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),nM,10.6,87547,DB00368,Norepinephrine
,17765221,K(i),"JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),nM,3.7,87548,DB00368,Norepinephrine
,17765221,oral bioavailability,"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),%,32,87549,DB00368,Norepinephrine
,17765221,half-life,"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),h,6.9,87550,DB00368,Norepinephrine
,17765221,C(max),"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),[ng] / [ml],260,87551,DB00368,Norepinephrine
,1975199,elimination half-life,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),h,1.7-2.0,87894,DB00368,Norepinephrine
,1975199,apparent volume of distribution,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),[l] / [kg],3.0-3.5,87895,DB00368,Norepinephrine
,1975199,total plasma clearance,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),[l] / [h·kg],1.1-1.5,87896,DB00368,Norepinephrine
,8489055,Cp50,"The Cp50 for fentanyl was 3.26 ng/ml, and the Cp50-BAR was 4.17 ng/ml.","Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489055/),[ng] / [ml],3.26,89419,DB00368,Norepinephrine
,8489055,Cp50-BAR,"The Cp50 for fentanyl was 3.26 ng/ml, and the Cp50-BAR was 4.17 ng/ml.","Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489055/),[ng] / [ml],4.17,89420,DB00368,Norepinephrine
,4008676,plasma half-life,"Following the administration of a single 90-mg oral dose of tomoxetine to four normal volunteers, the plasma half-life was 4.3 +/- 0.5 hours.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),h,4.3,91673,DB00368,Norepinephrine
,4008676,plasma clearance,"Mean plasma clearance was 0.60 +/- 0.14 L/Kg/hr, and the mean volume of distribution was 3.7 +/- 0.9 L/kg.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),[l] / [h·kg],0.60,91674,DB00368,Norepinephrine
,4008676,volume of distribution,"Mean plasma clearance was 0.60 +/- 0.14 L/Kg/hr, and the mean volume of distribution was 3.7 +/- 0.9 L/kg.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),[l] / [kg],3.7,91675,DB00368,Norepinephrine
,4008676,plasma half-life,The mean plasma half-life determined following the last dose was 4.6 +/- 0.5 hours in five subjects.,Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),h,4.6,91676,DB00368,Norepinephrine
,4008676,half-life,"The other two subjects, one at each dose level, demonstrated accumulation of tomoxetine occurring from the first to last dose where tomoxetine disappeared from plasma with a mean half-life of 19 hours.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),h,19,91677,DB00368,Norepinephrine
,3624412,plasma clearance rates,The plasma clearance rates of EPI and NE were nearly identical in the young subjects (1.63 +/- 0.14 vs. 166 +/- 0.09 L/min X m2; P = NS).,Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624412/),[l] / [m2·min],1.63,91872,DB00368,Norepinephrine
,3624412,plasma clearance rates,The plasma clearance rates of EPI and NE were nearly identical in the young subjects (1.63 +/- 0.14 vs. 166 +/- 0.09 L/min X m2; P = NS).,Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624412/),[l] / [m2·min],166,91873,DB00368,Norepinephrine
,2015725,ED50),In unrelated subjects the doses of norepinephrine constricting basal vein diameter by 50% (ED50) ranged from 3.9 to 120.5 ng/min.,Genetic aspects of variability in superficial vein responsiveness to norepinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015725/),[ng] / [min],3.9 to 120.5,92977,DB00368,Norepinephrine
,2015725,EC50),"Plasma concentrations of norepinephrine associated with reduction of basal vein diameter by 50% (EC50) ranged from 1.4 to 110.2 ng/ml, with variability similar to that of ED50.",Genetic aspects of variability in superficial vein responsiveness to norepinephrine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015725/),[ng] / [ml],1.4 to 110.2,92978,DB00368,Norepinephrine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB00368,Norepinephrine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB00368,Norepinephrine
,7690382,maximum concentration,"The mean maximum concentration in plasma for midodrine was 10 ng/ml 20-30 min after oral administration, for ST 1059 5 ng/ml after 1 h.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),[ng] / [ml],10,94148,DB00368,Norepinephrine
,7690382,maximum concentration,"The mean maximum concentration in plasma for midodrine was 10 ng/ml 20-30 min after oral administration, for ST 1059 5 ng/ml after 1 h.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),[ng] / [ml],5,94149,DB00368,Norepinephrine
,7690382,terminal half-life,"Midodrine was eliminated with a terminal half-life of 0.5 h, ST 1059 with a half-life of 3 hrs.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),h,0.5,94150,DB00368,Norepinephrine
,7690382,half-life,"Midodrine was eliminated with a terminal half-life of 0.5 h, ST 1059 with a half-life of 3 hrs.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),h,3,94151,DB00368,Norepinephrine
,7690382,area under the plasma-level vs. time curve (AUC),"The mean area under the plasma-level vs. time curve (AUC) of ST 1059 after administration of 2.5 mg midodrine i.v. was 28.7 ng x h/ml, and similar for the other formulations which are considered to be bioequivalent.",Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690382/),[h·ng] / [ml],28.7,94152,DB00368,Norepinephrine
,12083775,half-life,"The effectiveness of PET as a diagnostic tool, the convenient half-life of (18)F (110 min) and the favorable pharmacokinetics of 6-[(18)F]FDOPA have combined to make this an extremely valuable reagent to study dopaminergic activity.","Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083775/),min,110,95910,DB00368,Norepinephrine
,25637266,time to maximum plasma concentration,"The time to maximum plasma concentration of EDX was 2h, and the half-life was 9h.","A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637266/),h,2,96348,DB00368,Norepinephrine
,25637266,half-life,"The time to maximum plasma concentration of EDX was 2h, and the half-life was 9h.","A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637266/),h,9,96349,DB00368,Norepinephrine
,16764833,apparent terminal half-lives,"The apparent terminal half-lives of desvenlafaxine in plasma, brain and hypothalamus were 3.0, 2.1 and 2.5 h, respectively.",Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764833/),h,3.0,96660,DB00368,Norepinephrine
,16764833,apparent terminal half-lives,"The apparent terminal half-lives of desvenlafaxine in plasma, brain and hypothalamus were 3.0, 2.1 and 2.5 h, respectively.",Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764833/),h,2.1,96661,DB00368,Norepinephrine
,16764833,apparent terminal half-lives,"The apparent terminal half-lives of desvenlafaxine in plasma, brain and hypothalamus were 3.0, 2.1 and 2.5 h, respectively.",Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764833/),h,2.5,96662,DB00368,Norepinephrine
,10798303,limit of,The limit of quantification was about 15 ng/ml at 273 nm and about 4 ng/ml at 226 nm.,Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10798303/),ng,4,97408,DB00368,Norepinephrine
>,10798303,recovery rates,The day-to-day relative standard deviation ranged between 2.7 and 6.7% with recovery rates > or = 90%.,Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10798303/),%,90,97409,DB00368,Norepinephrine
,26256429,steady-state Cmax,"Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily).",Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),[ng] / [ml],93,98275,DB00368,Norepinephrine
,26256429,steady-state Cmax,"Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily).",Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),[ng] / [ml],180,98276,DB00368,Norepinephrine
,26256429,steady-state Cmax,"Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily).",Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),[ng] / [ml],297,98277,DB00368,Norepinephrine
,26256429,AUC0-τ,"Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily).",Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),[h·ng] / [ml],1520,98278,DB00368,Norepinephrine
,26256429,AUC0-τ,"Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily).",Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),[h·ng] / [ml],2935,98279,DB00368,Norepinephrine
,26256429,AUC0-τ,"Dose-proportional steady-state Cmax (93, 180, and 297 ng/mL) and AUC0-τ (1520, 2935, and 4799 ng*h/mL) were also observed in patients with MDD who received levomilnacipran ER (40, 80, and 120 mg daily).",Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),[h·ng] / [ml],4799,98280,DB00368,Norepinephrine
,26256429,Tmax,Tmax was ~6 hours and was similar after single and multiple oral doses of levomilnacipran ER.,Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26256429/),h,6,98281,DB00368,Norepinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],63,100616,DB00368,Norepinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],127,100617,DB00368,Norepinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],8,100618,DB00368,Norepinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],31,100619,DB00368,Norepinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,40-66,100620,DB00368,Norepinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,0.5,100621,DB00368,Norepinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,0.6-0.9,100622,DB00368,Norepinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,5.0-6.2,100623,DB00368,Norepinephrine
higher,15171932,extraction recoveries,The extraction recoveries were higher than 70% for both milnacipran and the internal standard.,"Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171932/),%,70,100768,DB00368,Norepinephrine
,2213571,Removal of,"Removal of MIBG [R(MIBG)] and R(AIBG) were 59 +/- 3% (n = 14) and 24 +/- 2% (n = 7), respectively.",Disposition of radioiodinated benzylguanidines in perfused rabbit lung: pharmacokinetics and effect of an organo-gold complexed antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213571/),%,59,101452,DB00368,Norepinephrine
,2213571,Removal of,"Removal of MIBG [R(MIBG)] and R(AIBG) were 59 +/- 3% (n = 14) and 24 +/- 2% (n = 7), respectively.",Disposition of radioiodinated benzylguanidines in perfused rabbit lung: pharmacokinetics and effect of an organo-gold complexed antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213571/),%,24,101453,DB00368,Norepinephrine
,2213571,R(,"Removal of MIBG [R(MIBG)] and R(AIBG) were 59 +/- 3% (n = 14) and 24 +/- 2% (n = 7), respectively.",Disposition of radioiodinated benzylguanidines in perfused rabbit lung: pharmacokinetics and effect of an organo-gold complexed antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213571/),%,59,101454,DB00368,Norepinephrine
,2213571,R(,"Removal of MIBG [R(MIBG)] and R(AIBG) were 59 +/- 3% (n = 14) and 24 +/- 2% (n = 7), respectively.",Disposition of radioiodinated benzylguanidines in perfused rabbit lung: pharmacokinetics and effect of an organo-gold complexed antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213571/),%,24,101455,DB00368,Norepinephrine
,8439023,minimum effective CSF clonidine concentration,Extrapolation of CSF clonidine pharmacokinetics suggests the minimum effective CSF clonidine concentration for postoperative pain relief is 76 +/- 15 ng/ml.,Hemodynamic and analgesic actions of epidurally administered clonidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439023/),[ng] / [ml],76,101547,DB00368,Norepinephrine
,1151803,Pa,"Foetal and maternal plasma catecholamine concentrations were measured during and after hypoxia (mean maternal Pa,02 44mmHg) in chronically catheterized sheep, 118-141 days pregnant.",Plasma catecholamines in foetal and adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1151803/),mmhg,44,102127,DB00368,Norepinephrine
,1151803,half-life,6. The half-life of adrenaline and of noradrenaline in the maternal and foetal circulation was 0.25-1 min.,Plasma catecholamines in foetal and adult sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1151803/),min,0.25-1,102128,DB00368,Norepinephrine
,12973468,terminal elimination half-life,Absorption is rapid and the terminal elimination half-life (13 h) allows twice-daily administration.,"Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973468/),h,13,104744,DB00368,Norepinephrine
,7428796,Pd1/2,It was possible to detect DTS for 228-300 h after the last oral dose and the mean Pd1/2 of this decline of pharmacodynamic effect was observed to be 135 h.,Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,135,106227,DB00368,Norepinephrine
,7428796,elimination plasma half-life (t1/2),"However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.",Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,37.7,106228,DB00368,Norepinephrine
,7428796,elimination plasma half-life (t1/2),"However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.",Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,38.9,106229,DB00368,Norepinephrine
,2014157,plasma t1/2,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),min,21,106641,DB00368,Norepinephrine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],1682,106642,DB00368,Norepinephrine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],486,106643,DB00368,Norepinephrine
,12005188,Ae(Azo,"The significantly greater Ae(Azo, 0-8 h) in 4WE rats was mainly due to a significant increase in intrinsic active secretion of azosemide in renal tubules and not due to a decrease in the metabolism of azosemide.",Influence of 4-week and 8-week exercise training on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12005188/),h,0-8,107367,DB00368,Norepinephrine
,19539103,methodologic recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,87.22,108120,DB00368,Norepinephrine
,19539103,extraction recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,113.75,108121,DB00368,Norepinephrine
,19539103,extraction recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,72.81,108122,DB00368,Norepinephrine
,19539103,extraction recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,89.96,108123,DB00368,Norepinephrine
,19539103,C(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],22.46,108124,DB00368,Norepinephrine
,19539103,C(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],44.40,108125,DB00368,Norepinephrine
,19539103,C(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],60.78,108126,DB00368,Norepinephrine
,19539103,AUC(0-60),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],328.64,108127,DB00368,Norepinephrine
,19539103,AUC(0-60),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],696.04,108128,DB00368,Norepinephrine
,19539103,AUC(0-60),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],1219.33,108129,DB00368,Norepinephrine
,19539103,AUC(0-infinity)),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],359.68,108130,DB00368,Norepinephrine
,19539103,AUC(0-infinity)),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],733.82,108131,DB00368,Norepinephrine
,19539103,AUC(0-infinity)),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],1280.51,108132,DB00368,Norepinephrine
,19539103,T(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.83,108133,DB00368,Norepinephrine
,19539103,T(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.10,108134,DB00368,Norepinephrine
,19539103,T(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.60,108135,DB00368,Norepinephrine
,19539103,t1/2,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,12.95,108136,DB00368,Norepinephrine
,19539103,t1/2,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,12.81,108137,DB00368,Norepinephrine
,19539103,t1/2,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,11.66,108138,DB00368,Norepinephrine
,19539103,CL,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),,107.90,108139,DB00368,Norepinephrine
,19539103,C(ssmax),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],47.33,108140,DB00368,Norepinephrine
,19539103,C(ssmm),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],27.92,108141,DB00368,Norepinephrine
,19539103,AUC(ss(0-t)),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],407.25,108142,DB00368,Norepinephrine
,19539103,C(ssav),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],33.94,108143,DB00368,Norepinephrine
,19539103,T(max),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.36,108144,DB00368,Norepinephrine
,19539103,t(1/2),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,11.19,108145,DB00368,Norepinephrine
,19539103,CL,Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[l] / [h],83.12,108146,DB00368,Norepinephrine
,19539103,V(d),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),l,1359.01,108147,DB00368,Norepinephrine
,7531352,apparent elimination half-life,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.0,108472,DB00368,Norepinephrine
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.5,108473,DB00368,Norepinephrine
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,2.5,108474,DB00368,Norepinephrine
,7531352,half-lives,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,3-4,108475,DB00368,Norepinephrine
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,4-6,108476,DB00368,Norepinephrine
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,12,108477,DB00368,Norepinephrine
,31522098,flow rate,"The derivatives resolved with good baseline separation on an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with mobile phase composed of methanol with 0.2% formic acid in water at a flow rate of 0.2 mL/min.",Analysis of endogenous epinephrine and norepinephrine enantiomers in rat plasma and application to a stereoselective pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31522098/),[ml] / [min],0.2,108604,DB00368,Norepinephrine
more,31522098,Recoveries,Recoveries for all the analytes were more than 80.3%.,Analysis of endogenous epinephrine and norepinephrine enantiomers in rat plasma and application to a stereoselective pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31522098/),%,80.3,108605,DB00368,Norepinephrine
,18954038,IC50,"Thus, compound 5c exhibited IC50 values of 2.3 and 32 nM, respectively, at NET and SERT, which were more than 10-fold better than those of 1 (NET IC50 = 77 nM, SERT IC50 = 420 nM).","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18954038/),nM,2.3,113866,DB00368,Norepinephrine
,18954038,IC50,"Thus, compound 5c exhibited IC50 values of 2.3 and 32 nM, respectively, at NET and SERT, which were more than 10-fold better than those of 1 (NET IC50 = 77 nM, SERT IC50 = 420 nM).","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18954038/),nM,32,113867,DB00368,Norepinephrine
,18954038,IC50,"Thus, compound 5c exhibited IC50 values of 2.3 and 32 nM, respectively, at NET and SERT, which were more than 10-fold better than those of 1 (NET IC50 = 77 nM, SERT IC50 = 420 nM).","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18954038/),nM,77,113868,DB00368,Norepinephrine
,18954038,IC50,"Thus, compound 5c exhibited IC50 values of 2.3 and 32 nM, respectively, at NET and SERT, which were more than 10-fold better than those of 1 (NET IC50 = 77 nM, SERT IC50 = 420 nM).","Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18954038/),nM,420,113869,DB00368,Norepinephrine
,20462211,IC(50),One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC(50) = 1.2 nM) and excellent selectivity for hNET over hSERT (>1600-fold) and hDAT (>600-fold).,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462211/),nM,1.2,115266,DB00368,Norepinephrine
,8105053,steady-state clearance,"The steady-state clearance of interferon g from the cell was 1.41 +/- 0.38 x 10(-3) mL min-1, and the absorption half-life (t1/2) was 3.8 +/- 1.1 h (n = 4).",Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105053/),[ml] / [min],1.41,120528,DB00368,Norepinephrine
,8105053,absorption half-life (t1/2),"The steady-state clearance of interferon g from the cell was 1.41 +/- 0.38 x 10(-3) mL min-1, and the absorption half-life (t1/2) was 3.8 +/- 1.1 h (n = 4).",Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105053/),h,3.8,120529,DB00368,Norepinephrine
,8105053,clearance,"Noradrenaline did not significantly alter either the clearance or absorption of interferon g (1.18 +/- 0.44 x 10(-3) mL min-1, P > 0.05, absorption t1/2 4.96 +/- 1.9 h, P > 0.05).",Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105053/),[ml] / [min],1.18,120530,DB00368,Norepinephrine
,8105053,absorption t1/2,"Noradrenaline did not significantly alter either the clearance or absorption of interferon g (1.18 +/- 0.44 x 10(-3) mL min-1, P > 0.05, absorption t1/2 4.96 +/- 1.9 h, P > 0.05).",Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105053/),h,4.96,120531,DB00368,Norepinephrine
,6826720,clearance,"Preoperatively, in the resting supine position, the clearance values based on arterial and venous sampling averaged 1.4 and 2.5 liter/min, respectively (P < 0.02).",Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[l] / [min],1.4,121709,DB00368,Norepinephrine
,6826720,clearance,"Preoperatively, in the resting supine position, the clearance values based on arterial and venous sampling averaged 1.4 and 2.5 liter/min, respectively (P < 0.02).",Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[l] / [min],2.5,121710,DB00368,Norepinephrine
,6826720,plasma NE,The mean plasma NE increased from 1.70 nmol/liter preoperatively to 5.20 nmol/liter postoperatively (P < 0.02).,Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[nM] / [l],1.70,121711,DB00368,Norepinephrine
,6826720,plasma NE,The mean plasma NE increased from 1.70 nmol/liter preoperatively to 5.20 nmol/liter postoperatively (P < 0.02).,Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[nM] / [l],5.20,121712,DB00368,Norepinephrine
,6826720,plasma appearance rate,The plasma appearance rate of NE averaged 2.4 nmol/min before surgery and it increased to 9.5 nmol/min postoperatively (P < 0.02).,Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[nM] / [min],2.4,121713,DB00368,Norepinephrine
,6826720,plasma appearance rate,The plasma appearance rate of NE averaged 2.4 nmol/min before surgery and it increased to 9.5 nmol/min postoperatively (P < 0.02).,Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[nM] / [min],9.5,121714,DB00368,Norepinephrine
,6826720,plasma clearance,"The plasma clearance of NE averaged 1.4 and 1.6 liter/min pre- and postoperatively, respectively (not significantly different).",Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[l] / [min],1.4,121715,DB00368,Norepinephrine
,6826720,plasma clearance,"The plasma clearance of NE averaged 1.4 and 1.6 liter/min pre- and postoperatively, respectively (not significantly different).",Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stress. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826720/),[l] / [min],1.6,121716,DB00368,Norepinephrine
,9356115,plasma concentration (Cp),"Dexmedetomidine was infused postoperatively by CCIP for 60 min to eight women, targeting a plasma concentration (Cp) of 600 pg/mL.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),[pg] / [ml],600,122551,DB00368,Norepinephrine
,9356115,heart rate,"During the infusion, norepinephrine decreased from 2.1 +/- 0.8 to 0.7 +/- 0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2 nmol/L; heart rate decreased from 76 +/- 15 to 64 +/- 11 bpm; and systolic blood pressure decreased from 158 +/- 23 to 140 +/- 23 mm Hg.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),bpm,76,122552,DB00368,Norepinephrine
,9356115,heart rate,"During the infusion, norepinephrine decreased from 2.1 +/- 0.8 to 0.7 +/- 0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2 nmol/L; heart rate decreased from 76 +/- 15 to 64 +/- 11 bpm; and systolic blood pressure decreased from 158 +/- 23 to 140 +/- 23 mm Hg.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),bpm,64,122553,DB00368,Norepinephrine
,22621882,flow rate,"The mobile phase consisted of acetonitrile (A):acetic acid (B) (33 mM), delivered in gradient mode (5-95% B [0-20 min], 95-5% B [20-25 min] and finally 5% B isocratically [25-32 min]) with a flow rate of 1 mL min⁻¹.",Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621882/),min⁻¹·ml,1,122791,DB00368,Norepinephrine
,22621882,recovery,"TAP was extracted from the plasma using a mixture of Et₂O:CH₂Cl₂ (7:3, v/v), which gave a recovery of 98.0-107.8% and a limit of quantification of 1 ng mL⁻¹.",Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621882/),%,98.0-107.8,122792,DB00368,Norepinephrine
,22621882,limit of quantification,"TAP was extracted from the plasma using a mixture of Et₂O:CH₂Cl₂ (7:3, v/v), which gave a recovery of 98.0-107.8% and a limit of quantification of 1 ng mL⁻¹.",Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621882/),ml⁻¹·ng,1,122793,DB00368,Norepinephrine
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,35.3,123919,DB00368,Norepinephrine
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,225,123920,DB00368,Norepinephrine
,27207183,absolute bioavailability,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),%,60.5,123921,DB00368,Norepinephrine
,27207183,LD50,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),[mg] / [kg],346,123922,DB00368,Norepinephrine
,16789796,peak plasma concentrations,"In children with ADHD, MTS patches releasing MPH doses of 10-30 mg over a 9-hour period (12.5-37.5 cm2 patch size) is steadily absorbed, with mean peak plasma concentrations of d-MPH (20-46.5 ng/mL) reached in approximately 8 hours.",Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16789796/),[ng] / [ml],20-46.5,123979,DB00368,Norepinephrine
,26233335,bioavailability,Intranasal bioavailability was 82%.,Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233335/),%,82,124283,DB00368,Norepinephrine
,22771148,half-life,"After IV administration, concentrations of TAP were detectable in plasma for up to 6h with a half-life in the range 38-68 min.",Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771148/),min,38-68,124535,DB00368,Norepinephrine
,22771148,bioavailability,"After oral administration, drug absorption was rapid (T(max), time required to reach the maximum concentration of 47.5 min), but its bioavailability was low (4.4%).",Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771148/),%,4.4,124536,DB00368,Norepinephrine
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,26,124601,DB00368,Norepinephrine
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,33,124602,DB00368,Norepinephrine
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,51,124603,DB00368,Norepinephrine
,7085853,Whole body clearance,"Whole body clearance of epinephrine, calculated from arterial measurements, was 33 +/- 3 ml/kg . min during the 0.1 microgram/min infusion and 35 +/- 3 ml/kg . min during the 2 micrograms/min epinephrine infusion, values 50% lower than the clearance rates calculated from venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],33,124604,DB00368,Norepinephrine
,7085853,Whole body clearance,"Whole body clearance of epinephrine, calculated from arterial measurements, was 33 +/- 3 ml/kg . min during the 0.1 microgram/min infusion and 35 +/- 3 ml/kg . min during the 2 micrograms/min epinephrine infusion, values 50% lower than the clearance rates calculated from venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],35,124605,DB00368,Norepinephrine
,7085853,whole body clearance,"Propranolol infusion resulted in a fall in whole body clearance to 20 +/- 2 ml/kg . min (P less than 0.001), suggesting that epinephrine clearance is partly dependent on a beta-adrenergic mechanism.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],20,124606,DB00368,Norepinephrine
,7085853,Basal endogenous release rate (clearance X,"Basal endogenous release rate (clearance X basal epinephrine level) was estimated to be approximately 0.18 microgram/min, a value much less than that reported in studies using venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[μg] / [min],0.18,124607,DB00368,Norepinephrine
,1317234,receptor occupancy,"In the alpha 1-radioreceptor assay, plasma concentrations from 0.9- to 1.7-fold the equilibrium dissociation constant (Ki) of carvedilol could be evaluated 1 as well as 3.5 h after medication, corresponding with a receptor occupancy of 44%-63%.",Oral administration of carvedilol and prazosin inhibits the prostaglandin F2 alpha- and noradrenaline-induced contraction of human hand veins in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317234/),%,44,125985,DB00368,Norepinephrine
,1572185,half-life,The half-life for the alpha phase was 2.2 mins and was 38.7 mins for the beta phase.,Plasma catecholamine concentrations after successful resuscitation in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),min,2.2,127274,DB00368,Norepinephrine
,1572185,half-life,The half-life for the alpha phase was 2.2 mins and was 38.7 mins for the beta phase.,Plasma catecholamine concentrations after successful resuscitation in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),min,38.7,127275,DB00368,Norepinephrine
,1572185,plasma glucose concentrations,Median plasma glucose concentrations were between 8.2 mmol/L (147.7 mg/dL; range 5.8 to 11.2 mmol/L [104.5 to 201.8 mg/dL]) at 1 min and 13.9 mmol/L (250.4 mg/dL; range 9.7 to 16.6 mmol/L [174.8 to 299.1 mg/dL]) at 30 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],8.2,127276,DB00368,Norepinephrine
,1572185,plasma glucose concentrations,Median plasma glucose concentrations were between 8.2 mmol/L (147.7 mg/dL; range 5.8 to 11.2 mmol/L [104.5 to 201.8 mg/dL]) at 1 min and 13.9 mmol/L (250.4 mg/dL; range 9.7 to 16.6 mmol/L [174.8 to 299.1 mg/dL]) at 30 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],13.9,127277,DB00368,Norepinephrine
,1572185,Lactate,Lactate values were between 11.4 mmol/L (range 4.7 to 16.5) at 1 min and 5.2 mmol/L (range 2.7 to 12.5) at 60 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],11.4,127278,DB00368,Norepinephrine
,1572185,Lactate,Lactate values were between 11.4 mmol/L (range 4.7 to 16.5) at 1 min and 5.2 mmol/L (range 2.7 to 12.5) at 60 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],5.2,127279,DB00368,Norepinephrine
,32935460,tmax,Solriamfetol median tmax was 2-3 hours; exposure was dose-proportional.,"A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935460/),h,2-3,128175,DB00368,Norepinephrine
,3316275,input rate into the extravascular compartment 2,"The NE input rate into the extravascular compartment 2, estimated with the minimal model, increased with upright posture (1.87 +/- 0.08 vs. 3.25 +/- 0.2 micrograms/min per m2, P less than 0.001).",Norepinephrine metabolism in humans. Kinetic analysis and model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3316275/),[μg] / [m2·min],1.87,128948,DB00368,Norepinephrine
,3316275,input rate into the extravascular compartment 2,"The NE input rate into the extravascular compartment 2, estimated with the minimal model, increased with upright posture (1.87 +/- 0.08 vs. 3.25 +/- 0.2 micrograms/min per m2, P less than 0.001).",Norepinephrine metabolism in humans. Kinetic analysis and model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3316275/),[μg] / [m2·min],3.25,128949,DB00368,Norepinephrine
,3316275,volume of distribution,"Upright posture was associated with a fall in the volume of distribution of NE in compartment 1 (7.5 +/- 0.6 vs. 4.7 +/- 0.3 liters, P less than 0.001), and as a result of that, there was a fall in the metabolic clearance rate of NE from compartment 1 (1.80 +/- 0.11 vs. 1.21 +/- 0.08 liters/min per m2, P less than 0.001).",Norepinephrine metabolism in humans. Kinetic analysis and model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3316275/),l,7.5,128950,DB00368,Norepinephrine
,3316275,volume of distribution,"Upright posture was associated with a fall in the volume of distribution of NE in compartment 1 (7.5 +/- 0.6 vs. 4.7 +/- 0.3 liters, P less than 0.001), and as a result of that, there was a fall in the metabolic clearance rate of NE from compartment 1 (1.80 +/- 0.11 vs. 1.21 +/- 0.08 liters/min per m2, P less than 0.001).",Norepinephrine metabolism in humans. Kinetic analysis and model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3316275/),l,4.7,128951,DB00368,Norepinephrine
,3316275,metabolic clearance rate,"Upright posture was associated with a fall in the volume of distribution of NE in compartment 1 (7.5 +/- 0.6 vs. 4.7 +/- 0.3 liters, P less than 0.001), and as a result of that, there was a fall in the metabolic clearance rate of NE from compartment 1 (1.80 +/- 0.11 vs. 1.21 +/- 0.08 liters/min per m2, P less than 0.001).",Norepinephrine metabolism in humans. Kinetic analysis and model. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3316275/),[l] / [m2·min],1.80,128952,DB00368,Norepinephrine
,3316275,metabolic clearance rate,"Upright posture was associated with a fall in the volume of distribution of NE in compartment 1 (7.5 +/- 0.6 vs. 4.7 +/- 0.3 liters, P less than 0.001), and as a result of that, there was a fall in the metabolic clearance rate of NE from compartment 1 (1.80 +/- 0.11 vs. 1.21 +/- 0.08 liters/min per m2, P less than 0.001).",Norepinephrine metabolism in humans. Kinetic analysis and model. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3316275/),[l] / [m2·min],1.21,128953,DB00368,Norepinephrine
,22849510,time to maximum concentration (t(max)),"The time to maximum concentration (t(max)) of edivoxetine was ∼2 hours, which was followed by a mono-exponential decline in plasma concentrations with a terminal elimination half-life (t(1/2)) of ∼6 hours.","Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849510/),h,∼2,129569,DB00368,Norepinephrine
,22849510,terminal elimination half-life (t(1/2)),"The time to maximum concentration (t(max)) of edivoxetine was ∼2 hours, which was followed by a mono-exponential decline in plasma concentrations with a terminal elimination half-life (t(1/2)) of ∼6 hours.","Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849510/),h,∼6,129570,DB00368,Norepinephrine
,2015726,maximal increase,"Twelve milligrams of yohimbine moderately but significantly accelerated supine heart rate (mean maximal increase, 7 +/- 3 beats/min).",The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015726/),[beats] / [min],7,131264,DB00368,Norepinephrine
,15910008,Absolute oral bioavailability,"Absolute oral bioavailability ranges from 63 to 94%, which is governed by the extent of its first-pass metabolism.",Clinical pharmacokinetics of atomoxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),%,63 to 94,131464,DB00368,Norepinephrine
,15910008,plasma half-life,"In extensive metabolisers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolisers, atomoxetine has a plasma half-life of 21.6 hours.",Clinical pharmacokinetics of atomoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),h,5.2,131465,DB00368,Norepinephrine
,15910008,plasma half-life,"In extensive metabolisers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolisers, atomoxetine has a plasma half-life of 21.6 hours.",Clinical pharmacokinetics of atomoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),h,21.6,131466,DB00368,Norepinephrine
,15910008,systemic plasma clearance,"The systemic plasma clearance of atomoxetine is 0.35 and 0.03 L/h/kg in extensive and poor metabolisers, respectively.",Clinical pharmacokinetics of atomoxetine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),[l] / [h·kg],0.35,131467,DB00368,Norepinephrine
,15910008,systemic plasma clearance,"The systemic plasma clearance of atomoxetine is 0.35 and 0.03 L/h/kg in extensive and poor metabolisers, respectively.",Clinical pharmacokinetics of atomoxetine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),[l] / [h·kg],0.03,131468,DB00368,Norepinephrine
,15910008,volume of distribution,"The volume of distribution is 0.85 L/kg, indicating that atomoxetine is distributed in total body water in both extensive and poor metabolisers.",Clinical pharmacokinetics of atomoxetine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),[l] / [kg],0.85,131469,DB00368,Norepinephrine
,2089102,Ki,Ro 40-7592 was found to inhibit COMT in a competitive fashion both in the CNS and in the periphery (Ki for the liver enzyme = 30 nM).,Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089102/),nM,30,131877,DB00368,Norepinephrine
,1833892,arterial blood flow,"Peak effects on all measurements were observed at 1 h and coincided with peak plasma concentrations: QS2c shortened by 36 +/- 13 ms (mean +/- SD; p less than 0.01 compared to placebo); arterial blood flow increased from 2.10 +/- 0.58 to 4.32 +/- 1.26 ml 100 ml-1 min-1 (mean +/- SD; p less than 0.01 compared to placebo); norepinephrine dose-response curves shifted to the right (p less than 0.01 with 20-320 ng/min compared to baseline), i.e., to achieve the same vasoconstriction as before enoximone a 3-to-5-times higher dose of norepinephrine was needed.","[Effect of oral administration of enoximone on cardiac performance, arterial circulation at rest and on the vasoconstrictor effect of local noradrenaline infusions into the human hand vein]. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1833892/),[100·ml] / [min·ml],2.10,133571,DB00368,Norepinephrine
,1833892,arterial blood flow,"Peak effects on all measurements were observed at 1 h and coincided with peak plasma concentrations: QS2c shortened by 36 +/- 13 ms (mean +/- SD; p less than 0.01 compared to placebo); arterial blood flow increased from 2.10 +/- 0.58 to 4.32 +/- 1.26 ml 100 ml-1 min-1 (mean +/- SD; p less than 0.01 compared to placebo); norepinephrine dose-response curves shifted to the right (p less than 0.01 with 20-320 ng/min compared to baseline), i.e., to achieve the same vasoconstriction as before enoximone a 3-to-5-times higher dose of norepinephrine was needed.","[Effect of oral administration of enoximone on cardiac performance, arterial circulation at rest and on the vasoconstrictor effect of local noradrenaline infusions into the human hand vein]. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1833892/),[100·ml] / [min·ml],4.32,133572,DB00368,Norepinephrine
,10190880,Baroreflex sensitivity,"Baroreflex sensitivity was lower in patients (12+/-1 versus 18+/-2 ms/mm Hg, P<0.02), but the intrinsic heart rate was similar in both groups.",Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190880/),[ms] / [hg·mm],12,134898,DB00368,Norepinephrine
,10190880,Baroreflex sensitivity,"Baroreflex sensitivity was lower in patients (12+/-1 versus 18+/-2 ms/mm Hg, P<0.02), but the intrinsic heart rate was similar in both groups.",Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190880/),[ms] / [hg·mm],18,134899,DB00368,Norepinephrine
,12920170,total recovery of radioactivity,The mean total recovery of radioactivity (+/- S.E.M.) after 312 h was 90.5% (+/-0.4%) with 72.0% (+/-1.1%) excreted in the urine.,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),%,90.5,136272,DB00368,Norepinephrine
,12920170,total recovery of radioactivity,The mean total recovery of radioactivity (+/- S.E.M.) after 312 h was 90.5% (+/-0.4%) with 72.0% (+/-1.1%) excreted in the urine.,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),%,72.0,136273,DB00368,Norepinephrine
,12920170,elimination half-life,The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),h,120,136274,DB00368,Norepinephrine
,12920170,elimination half-life,The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),h,10.3,136275,DB00368,Norepinephrine
<,21508084,t(1/2),"Profiling of AMN082 in rat liver microsomes revealed rapid metabolism (t(1/2) < 1 min) to a major metabolite, N-benzhydrylethane-1,2-diamine (Met-1).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),min,1,139081,DB00368,Norepinephrine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,323,139082,DB00368,Norepinephrine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,3020,139083,DB00368,Norepinephrine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,3410,139084,DB00368,Norepinephrine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,1385,139085,DB00368,Norepinephrine
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],47,143268,DB00368,Norepinephrine
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],110,143269,DB00368,Norepinephrine
,21366359,elimination half-life,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),h,10-12,143270,DB00368,Norepinephrine
,21366359,volume of distribution,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),l,1640,143271,DB00368,Norepinephrine
,16227334,CL,"CL and T(1/2) varied from 3 litre min(-1) and 2 min, respectively, when SAPS II=20 to 0.9 litre min(-1) and 6.8 min when SAPS II=60.",Norepinephrine kinetics and dynamics in septic shock and trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227334/),[l] / [min],3,144950,DB00368,Norepinephrine
,16227334,T(1/2),"CL and T(1/2) varied from 3 litre min(-1) and 2 min, respectively, when SAPS II=20 to 0.9 litre min(-1) and 6.8 min when SAPS II=60.",Norepinephrine kinetics and dynamics in septic shock and trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227334/),min,2,144951,DB00368,Norepinephrine
,16227334,T(1/2),"CL and T(1/2) varied from 3 litre min(-1) and 2 min, respectively, when SAPS II=20 to 0.9 litre min(-1) and 6.8 min when SAPS II=60.",Norepinephrine kinetics and dynamics in septic shock and trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227334/),min,6.8,144952,DB00368,Norepinephrine
,2682731,halflife time,Acute pharmacokinetic data showed a wide interindividual range with a mean halflife time of 6.0 h.,Clozapine--pharmacokinetic investigations and biochemical effects in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2682731/),h,6.0,145385,DB00368,Norepinephrine
,15666063,half-time,"Plasma L-DOPS peaked at 1.9 microg/ml (9 micromol/L) about 3 hours after drug administration, followed by a monoexponential decline with a half-time of 2-3 hours in both patient groups.",Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15666063/),h,2-3,148243,DB00368,Norepinephrine
,3907374,Urinary sodium excretions,"Urinary sodium excretions were 22 +/- 4, 202 +/- 19, and 1,052 +/- 86 meq/day.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[meq] / [d],22,148476,DB00368,Norepinephrine
,3907374,Urinary sodium excretions,"Urinary sodium excretions were 22 +/- 4, 202 +/- 19, and 1,052 +/- 86 meq/day.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[meq] / [d],202,148477,DB00368,Norepinephrine
,3907374,Urinary sodium excretions,"Urinary sodium excretions were 22 +/- 4, 202 +/- 19, and 1,052 +/- 86 meq/day.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[meq] / [d],"1,052",148478,DB00368,Norepinephrine
,3907374,inulin clearance,"From the lower to the upper sodium intake level, 24-h creatinine clearance rose from 111 +/- 7 to 136 +/- 11 ml/min and inulin clearance from 103 +/- 9 to 129 +/- 9 ml/min, whereas proximal and distal fractional sodium reabsorption (FSRprox and FSRdist, respectively) fell from 86.8 +/- 1.3 to 79.0 +/- 2.7% and from 96.5 +/- 0.5 to 76.0 +/- 1.9%, respectively.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[ml] / [min],103,148479,DB00368,Norepinephrine
,3907374,inulin clearance,"From the lower to the upper sodium intake level, 24-h creatinine clearance rose from 111 +/- 7 to 136 +/- 11 ml/min and inulin clearance from 103 +/- 9 to 129 +/- 9 ml/min, whereas proximal and distal fractional sodium reabsorption (FSRprox and FSRdist, respectively) fell from 86.8 +/- 1.3 to 79.0 +/- 2.7% and from 96.5 +/- 0.5 to 76.0 +/- 1.9%, respectively.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[ml] / [min],129,148480,DB00368,Norepinephrine
,21318594,absolute bioavailability,"Following intranasal administration, peak plasma concentrations of dexmedetomidine were reached in 38 (15-60) min and its absolute bioavailability was 65% (35-93%) (medians and ranges).",Bioavailability of dexmedetomidine after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318594/),%,65,148902,DB00368,Norepinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],178,149399,DB00368,Norepinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],205,149400,DB00368,Norepinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],193,149401,DB00368,Norepinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],170,149402,DB00368,Norepinephrine
,2354553,steady state concentrations,2. In patients and volunteers steady state concentrations of free DA showing fairly large inter-individual variations (12.4-73.4 micrograms/L) were reached within 10 min of the beginning of the infusion.,Dopamine infusion in healthy subjects and critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[μg] / [l],12.4-73.4,150239,DB00368,Norepinephrine
,2354553,steady state concentrations,In patients steady state concentrations of conjugated DA (63-80 micrograms/L) were reached within 5-10 h of DA infusion.,Dopamine infusion in healthy subjects and critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[μg] / [l],63-80,150240,DB00368,Norepinephrine
,2354553,distribution volumes,The large distribution volumes of 19.8-75 L/kg indicate that DA has been taken up by peripheral tissues.,Dopamine infusion in healthy subjects and critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[l] / [kg],19.8-75,150241,DB00368,Norepinephrine
,2354553,clearance,5. Substantial inter-individual variations in the patients' clearance of free DA (3.9-16.5 L/kg per h) may partly explain the variability in haemodynamic responses to DA infusion reported in clinical studies.,Dopamine infusion in healthy subjects and critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[l] / [h·kg],3.9-16.5,150242,DB00368,Norepinephrine
,15671203,CL,"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[l] / [h],41.2 to 27.4,153609,DB00368,Norepinephrine
,15671203,V,"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),l,131,153610,DB00368,Norepinephrine
,15671203,Q,"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[l] / [h],1.7,153611,DB00368,Norepinephrine
,15671203,V(p),"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),l,36,153612,DB00368,Norepinephrine
,15671203,k(a),"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),1/[h],1.85,153613,DB00368,Norepinephrine
,15671203,production rate of DHPG (k(in)),"The production rate of DHPG (k(in)) was 2540 ng . h(-1), reduced by 63% at maximal CHF3381 concentrations.","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[ng] / [h],2540,153614,DB00368,Norepinephrine
,15671203,EC(50),"EC(50) was 1670 mug/l, not significantly different from the in vitro IC(50).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[μg] / [l],1670,153615,DB00368,Norepinephrine
,15671203,heart rate,The increase in heart rate due to CHF3381 was 0.0055 bpm/micro(g l-1).,"Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[bpm] / [l·μ(g],0.0055,153616,DB00368,Norepinephrine
,22235148,ED(50),"Duloxetine exhibited selectivity for occupancy of SERT over NET in rat spinal cord with ED(50) values of 1 and 9 mg/kg, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[mg] / [kg],1,154892,DB00368,Norepinephrine
,22235148,ED(50),"Duloxetine exhibited selectivity for occupancy of SERT over NET in rat spinal cord with ED(50) values of 1 and 9 mg/kg, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[mg] / [kg],9,154893,DB00368,Norepinephrine
,22235148,EC(50),Corresponding EC(50) values for the inhibition of SERT and NET based on unbound duloxetine spinal cord concentrations were 0.5 and 8 nM.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),nM,0.5,154894,DB00368,Norepinephrine
,22235148,EC(50),Corresponding EC(50) values for the inhibition of SERT and NET based on unbound duloxetine spinal cord concentrations were 0.5 and 8 nM.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),nM,8,154895,DB00368,Norepinephrine
,22235148,plasma EC(50),"Duloxetine inhibited SERT and NET in rat spinal cord with a plasma EC(50) of 2.95 and 59.0 ng/ml, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],2.95,154896,DB00368,Norepinephrine
,22235148,plasma EC(50),"Duloxetine inhibited SERT and NET in rat spinal cord with a plasma EC(50) of 2.95 and 59.0 ng/ml, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],59.0,154897,DB00368,Norepinephrine
,22235148,plasma,Similar plasma EC(50) values for the inhibition of SERT (2.29-3.7 ng/ml) have been reported from human PET studies.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],2.29-3.7,154898,DB00368,Norepinephrine
,22235148,EC(50),Similar plasma EC(50) values for the inhibition of SERT (2.29-3.7 ng/ml) have been reported from human PET studies.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],2.29-3.7,154899,DB00368,Norepinephrine
,2591463,tmax,"After 1 and 5 mg, tmax ranged from 1-2 h; Cmax (4.1 to 20.8 ng.ml-1; AUC (0-24) 20 to 132 ng.",Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591463/),h,1-2,155235,DB00368,Norepinephrine
,2591463,Cmax,"After 1 and 5 mg, tmax ranged from 1-2 h; Cmax (4.1 to 20.8 ng.ml-1; AUC (0-24) 20 to 132 ng.",Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591463/),[ng] / [ml],4.1 to 20.8,155236,DB00368,Norepinephrine
,2591463,AUC (0-24),"After 1 and 5 mg, tmax ranged from 1-2 h; Cmax (4.1 to 20.8 ng.ml-1; AUC (0-24) 20 to 132 ng.",Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591463/),ng,20 to 132,155237,DB00368,Norepinephrine
,11861324,elimination half-life,"2. In control rats, the elimination half-life of pirfenidone following a single intravenous dose of 200 mg kg(-1) was 37 min while oral bioavailability at this dose was 25.7%.",Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),min,37,155643,DB00368,Norepinephrine
,11861324,oral bioavailability,"2. In control rats, the elimination half-life of pirfenidone following a single intravenous dose of 200 mg kg(-1) was 37 min while oral bioavailability at this dose was 25.7%.",Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),%,25.7,155644,DB00368,Norepinephrine
,11861324,EC50,5. Noradrenaline potency (positive chronotropy) was decreased in right atria (neg log EC50: control 6.92 +/- 0.06; DOCA-salt 6.64 +/- 0.08); pirfenidone but not amiloride reversed this change.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,6.92,155645,DB00368,Norepinephrine
,11861324,EC50,5. Noradrenaline potency (positive chronotropy) was decreased in right atria (neg log EC50: control 6.92 +/- 0.06; DOCA-salt 6.64 +/- 0.08); pirfenidone but not amiloride reversed this change.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,6.64,155646,DB00368,Norepinephrine
,11861324,EC50,Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg log EC50: control 6.91 +/- 0.10; DOCA-salt 7.90 +/- 0.07); pirfenidone treatment did not change noradrenaline potency.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,6.91,155647,DB00368,Norepinephrine
,11861324,EC50,Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg log EC50: control 6.91 +/- 0.10; DOCA-salt 7.90 +/- 0.07); pirfenidone treatment did not change noradrenaline potency.,Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861324/),,7.90,155648,DB00368,Norepinephrine
,29666901,bioavailability,"The mean bioavailability of SC dexmedetomidine was 81% (AUC0-∞ ratio × 100%, range 49-97%).",Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29666901/),%,81,157406,DB00368,Norepinephrine
×,29666901,AUC0-∞ ratio,"The mean bioavailability of SC dexmedetomidine was 81% (AUC0-∞ ratio × 100%, range 49-97%).",Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29666901/),%,100,157407,DB00368,Norepinephrine
,29666901,peak concentration,"The mean (SD) peak concentration of dexmedetomidine in plasma was 0.3 (0.1) ng/ml, and plasma concentrations associated with sedative effects (i.e., > 0.2 ng/ml) were maintained for 4 h after SC dosing.",Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29666901/),[ng] / [ml],0.3,157408,DB00368,Norepinephrine
,20167039,NE release into the extravascular compartment (NE(2)),"Within 1 week of starting the HFD, NE release into the extravascular compartment (NE(2)) increased from 3.44+/-0.59 microg/mL to 4.87+/-0.80 microg/mL (P<.01) and this increase was maintained over the next 5 weeks of the HFD (NE(2) at week 6 was 4.66+/-0.97 microg/mL).",Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167039/),[μg] / [ml],3.44,158366,DB00368,Norepinephrine
,20167039,NE release into the extravascular compartment (NE(2)),"Within 1 week of starting the HFD, NE release into the extravascular compartment (NE(2)) increased from 3.44+/-0.59 microg/mL to 4.87+/-0.80 microg/mL (P<.01) and this increase was maintained over the next 5 weeks of the HFD (NE(2) at week 6 was 4.66+/-0.97 microg/mL).",Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167039/),[μg] / [ml],4.87,158367,DB00368,Norepinephrine
,20167039,NE(2),"Within 1 week of starting the HFD, NE release into the extravascular compartment (NE(2)) increased from 3.44+/-0.59 microg/mL to 4.87+/-0.80 microg/mL (P<.01) and this increase was maintained over the next 5 weeks of the HFD (NE(2) at week 6 was 4.66+/-0.97 microg/mL).",Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167039/),[μg] / [ml],4.66,158368,DB00368,Norepinephrine
,7705434,IC50,"YM-26365 inhibited human plasma renin with an IC50 value of 2.9 x 10(-6) M, but did not affect plasma renin from dogs, rabbits, and rats at 10(-4) M. YM-26365 inhibited not only human renin, but also cathepsin D with an IC50 value of 1.7 x 10(-5) M.","Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),M,2.9 x 10(-6),158654,DB00368,Norepinephrine
,7705434,IC50,"YM-26365 inhibited human plasma renin with an IC50 value of 2.9 x 10(-6) M, but did not affect plasma renin from dogs, rabbits, and rats at 10(-4) M. YM-26365 inhibited not only human renin, but also cathepsin D with an IC50 value of 1.7 x 10(-5) M.","Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),M,1.7 x 10(-5),158655,DB00368,Norepinephrine
,7705434,Ki,This compound competitively inhibited the reaction between recombinant human renin and N-acetyl tetradecapeptide with a Ki value of 1.1 x 10(-6) M.,"Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),M,1.1 x 10(-6),158656,DB00368,Norepinephrine
,7705434,Systemic bioavailability,Systemic bioavailability as determined on the basis of the ratio of the total area under the plasma concentration-time curve after 3 mg/kg i.v. and 30 mg/kg orally to rats was 9.6%.,"Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),%,9.6,158657,DB00368,Norepinephrine
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB00368,Norepinephrine
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB00368,Norepinephrine
,27442605,V,"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),l,63.4,159028,DB00368,Norepinephrine
,27442605,maximum rate [Vm],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [h],9.57,159029,DB00368,Norepinephrine
,27442605,Michaelis constant [Km],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [l],1.97,159030,DB00368,Norepinephrine
,27442605,elimination half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,20,159031,DB00368,Norepinephrine
,27442605,half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,9,159032,DB00368,Norepinephrine
,11324717,constant flow rate,The liver was perfused in a recirculating system at a constant flow rate of 20 ml/min.,The effects of norepinephrine and prostaglandin E1 on pharmacokinetics of lidocaine in isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11324717/),[ml] / [min],20,159488,DB00368,Norepinephrine
,27311027,m,"The precursor-to-product ion transitions m/z 214.2→m/z 152.0 for droxidopa, and m/z 258.1→m/z 139.1 for IS were used for quantification.",Development and validation of a UPLC-MS/MS method for quantitation of droxidopa in human plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311027/),,214.2,160254,DB00368,Norepinephrine
,27311027,m/z,"The precursor-to-product ion transitions m/z 214.2→m/z 152.0 for droxidopa, and m/z 258.1→m/z 139.1 for IS were used for quantification.",Development and validation of a UPLC-MS/MS method for quantitation of droxidopa in human plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311027/),,258.1,160255,DB00368,Norepinephrine
,27311027,m/z,"The precursor-to-product ion transitions m/z 214.2→m/z 152.0 for droxidopa, and m/z 258.1→m/z 139.1 for IS were used for quantification.",Development and validation of a UPLC-MS/MS method for quantitation of droxidopa in human plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311027/),,139.1,160256,DB00368,Norepinephrine
,19805643,excretion,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[nM] / [24·h],52,160613,DB00368,Norepinephrine
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.25,160614,DB00368,Norepinephrine
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.22,160615,DB00368,Norepinephrine
,32399634,overall elimination half-life,Naphyrone pharmacokinetics followed a two-compartment model with an overall elimination half-life of 0.3 h.,The neurobehavioral effects of the designer drug naphyrone - an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399634/),h,0.3,161634,DB00368,Norepinephrine
,32399634,EC50,The naphyrone concentration/locomotor effect relationship was described by an additive Emax model with an EC50 of 672 μg/L.,The neurobehavioral effects of the designer drug naphyrone - an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399634/),[μg] / [l],672,161635,DB00368,Norepinephrine
,32254828,limits of detection (LODs),"The fibers were then successfully employed for simultaneous in vivo sampling of tetrodotoxin (TTX) and sulfonamides (SAs) in the dorsal-epaxial muscle of living pufferfish (Takifugu obscurus), and satisfactory sensitivities with limits of detection (LODs) in the range of 0.52-2.30 ng g-1 and comparable accuracies to the conventional liquid extraction (LE) method were achieved.",PLGA-based nanofibers with a biomimetic polynoradrenaline sheath for rapid in vivo sampling of tetrodotoxin and sulfonamides in pufferfish. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32254828/),[ng] / [g],0.52-2.30,165232,DB00368,Norepinephrine
,29615471,Ki,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,4.81,166369,DB00368,Norepinephrine
,29615471,Ki,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,6.72,166370,DB00368,Norepinephrine
,29615471,IC50,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,60.37,166371,DB00368,Norepinephrine
,26150701,maximum plasma concentration,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ng] / [ml],83.9,166613,DB00368,Norepinephrine
,26150701,maximum plasma concentration,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ng] / [ml],81.8,166614,DB00368,Norepinephrine
,26150701,maximum plasma concentration,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ng] / [ml],98.7,166615,DB00368,Norepinephrine
,26150701,maximum plasma concentration,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ng] / [ml],122.1,166616,DB00368,Norepinephrine
,26150701,area under the curve from time zero to infinity,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[h·ng] / [ml],"2,101.0",166617,DB00368,Norepinephrine
,26150701,area under the curve from time zero to infinity,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[h·ng] / [ml],"2,587.8",166618,DB00368,Norepinephrine
,26150701,area under the curve from time zero to infinity,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[h·ng] / [ml],"4,016.4",166619,DB00368,Norepinephrine
,26150701,area under the curve from time zero to infinity,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[h·ng] / [ml],"5,900.8",166620,DB00368,Norepinephrine
,26150701,terminal elimination half-life,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),,13.5,166621,DB00368,Norepinephrine
,26150701,terminal elimination half-life,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),,17.3,166622,DB00368,Norepinephrine
,26150701,terminal elimination half-life,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),,19.1,166623,DB00368,Norepinephrine
,26150701,terminal elimination half-life,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),,27.7,166624,DB00368,Norepinephrine
,26150701,renal clearance,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ml] / [min],175.9,166625,DB00368,Norepinephrine
,26150701,renal clearance,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ml] / [min],114.7,166626,DB00368,Norepinephrine
,26150701,renal clearance,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ml] / [min],69.9,166627,DB00368,Norepinephrine
,26150701,renal clearance,"Following administration of levomilnacipran, mean (standard deviation) maximum plasma concentration in participants with normal renal function, and mild, moderate, or severe renal impairment was 83.9 (21.0), 81.8 (23.4), 98.7 (18.1), and 122.1 (35.1) (ng/mL), respectively; area under the curve from time zero to infinity was 2,101.0 (516.9), 2,587.8 (649.9), 4,016.4 (995.4), and 5,900.8 (1,799.3) (h · ng/mL), respectively; terminal elimination half-life was 13.5 (2.8), 17.3 (3.5), 19.1 (4.6), and 27.7 (7.4) (hours), respectively; and renal clearance was 175.9 mL/min, 114.7 mL/min, 69.9 mL/min, and 28.6 mL/min, respectively.",Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),[ml] / [min],28.6,166628,DB00368,Norepinephrine
,26150701,maximum daily maintenance dose,No dose adjustment is required for individuals with mild renal impairment; the recommended maximum daily maintenance dose of levomilnacipran ER should not exceed 80 mg for individuals with moderate renal impairment and 40 mg for individuals with severe renal impairment.,Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150701/),,80,166629,DB00368,Norepinephrine
,29392574,Cmax,"Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h).",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),[ng] / [ml],2057,166763,DB00368,Norepinephrine
,29392574,Cmax,"Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h).",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),[ng] / [ml],3160,166764,DB00368,Norepinephrine
,29392574,AUC,"Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h).",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),[h·ng] / [ml],"10,927",166765,DB00368,Norepinephrine
,29392574,AUC,"Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h).",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),[h·ng] / [ml],"13,857",166766,DB00368,Norepinephrine
,29392574,tmax,"Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h).",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),h,4.00,166767,DB00368,Norepinephrine
,29392574,tmax,"Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h).",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),h,2.00,166768,DB00368,Norepinephrine
,29392574,t½e,Differences between the fed and fasted state for mean t½e (2.58 vs 2.68 h) were not observed.,Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),h,2.58,166769,DB00368,Norepinephrine
,29392574,t½e,Differences between the fed and fasted state for mean t½e (2.58 vs 2.68 h) were not observed.,Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),h,2.68,166770,DB00368,Norepinephrine
,29392574,Cmax,"With TID dosing, similar values for Cmax were observed after each dose (range 2789-3389 ng/mL) with no return to baseline between doses.",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),[ng] / [ml],2789-3389,166771,DB00368,Norepinephrine
,29392574,Cmax,"Norepinephrine Cmax was 895 pg/mL following dose 1, with no further increases upon subsequent doses; norepinephrine levels remained above baseline for 12-16 h after dose 1.",Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29392574/),[pg] / [ml],895,166772,DB00368,Norepinephrine
,1358496,time to maximum concentration,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),h,1.6 to 1.7,169292,DB00368,Norepinephrine
,1358496,elimination half-life,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),h,1.6 to 2.4,169293,DB00368,Norepinephrine
,1358496,apparent total plasma clearance,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),[l] / [h·kg],0.7 to 0.9,169294,DB00368,Norepinephrine
,1358496,apparent volume of distribution,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),[l] / [kg],2.1 to 2.6,169295,DB00368,Norepinephrine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[mg] / [kg],0.44,171181,DB00368,Norepinephrine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[ng] / [ml],24.5,171182,DB00368,Norepinephrine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[mg] / [kg],0.11,171183,DB00368,Norepinephrine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[ng] / [ml],4.4,171184,DB00368,Norepinephrine
,29036640,serum elimination half-life,"Although serum concentrations at early time points were lacking, the obtained curve was consistent with a two-compartment model and indicated a serum elimination half-life of 37 h.",Toxicokinetics of the Synthetic Cathinone α-Pyrrolidinohexanophenone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29036640/),h,37,171416,DB00368,Norepinephrine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],734,173027,DB00368,Norepinephrine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],630,173028,DB00368,Norepinephrine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],894,173029,DB00368,Norepinephrine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],1083,173030,DB00368,Norepinephrine
,8796829,clearance rate,"Fetal-placental cocaine clearance rate was independent of dose (337 +/- 39 mL/kg/minute), indicating that it is a first-order pharmacokinetic process.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[ml] / [kg·min],337,173366,DB00368,Norepinephrine
,8796829,heart rate,"There were significant increases in fetal heart rate (from 169 +/- 11 to 242 +/- 36 beats per minute), mean blood pressure (from 53 +/- 4 to 63 +/- 5 mmHg), and systolic blood pressure (from 68 +/- 2 to 80 +/- 5 mmHg), with a corresponding increase in catecholamine levels seen in the fetuses infused with 0.2 mg/kg/minute.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[beats] / [min],169,173367,DB00368,Norepinephrine
,8796829,heart rate,"There were significant increases in fetal heart rate (from 169 +/- 11 to 242 +/- 36 beats per minute), mean blood pressure (from 53 +/- 4 to 63 +/- 5 mmHg), and systolic blood pressure (from 68 +/- 2 to 80 +/- 5 mmHg), with a corresponding increase in catecholamine levels seen in the fetuses infused with 0.2 mg/kg/minute.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[beats] / [min],242,173368,DB00368,Norepinephrine
,1572184,plasma clearance rates,Dobutamine plasma clearance rates ranged from 40 to 130 mL/kg/min.,Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572184/),[ml] / [kg·min],40 to 130,173638,DB00368,Norepinephrine
,6378605,spillover rate into plasma,"As measured with the isotope dilution method using steady state kinetics, basal NE spillover rate into plasma was 203 +/- 92 ng/min; this level fell by 91 +/- 2% (P less than 0.001) to 24 +/- 13 ng/min during anesthesia.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],203,174251,DB00368,Norepinephrine
,6378605,spillover rate into plasma,"As measured with the isotope dilution method using steady state kinetics, basal NE spillover rate into plasma was 203 +/- 92 ng/min; this level fell by 91 +/- 2% (P less than 0.001) to 24 +/- 13 ng/min during anesthesia.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],24,174252,DB00368,Norepinephrine
,6378605,clearance rate,"Before pentobarbital administration, the NE clearance rate from plasma was 1.7 +/- 0.4 liters/min; this rate fell during anesthesia by 71 +/- 6% (P less than 0.001) to 0.5 +/- 0.2 liters/min.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],1.7,174253,DB00368,Norepinephrine
,6378605,clearance rate,"Before pentobarbital administration, the NE clearance rate from plasma was 1.7 +/- 0.4 liters/min; this rate fell during anesthesia by 71 +/- 6% (P less than 0.001) to 0.5 +/- 0.2 liters/min.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],0.5,174254,DB00368,Norepinephrine
,6378605,spillover rate into plasma,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],209,174255,DB00368,Norepinephrine
,6378605,spillover rate into plasma,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],204,174256,DB00368,Norepinephrine
,6378605,clearance of,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],1.8,174257,DB00368,Norepinephrine
,6378605,clearance of,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],1.7,174258,DB00368,Norepinephrine
,28827023,total plasma concentrations,"Median (interquartile) total plasma concentrations for l- and d-methadone were 50.78 ng/mL (30.6-113.0 ng/mL) and 62.0 ng/mL (28.7-116.0 ng/mL), respectively.",Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],50.78,174441,DB00368,Norepinephrine
,28827023,total plasma concentrations,"Median (interquartile) total plasma concentrations for l- and d-methadone were 50.78 ng/mL (30.6-113.0 ng/mL) and 62.0 ng/mL (28.7-116.0 ng/mL), respectively.",Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],62.0,174442,DB00368,Norepinephrine
,28827023,saliva concentrations,Median (interquartile range) saliva concentrations for l- and d-methadone were 81.5 ng/mL (28.0-203.2 ng/mL) and 44.2 (16.2-149.7 ng/mL).,Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],81.5,174443,DB00368,Norepinephrine
,28827023,saliva concentrations,Median (interquartile range) saliva concentrations for l- and d-methadone were 81.5 ng/mL (28.0-203.2 ng/mL) and 44.2 (16.2-149.7 ng/mL).,Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827023/),[ng] / [ml],44.2,174444,DB00368,Norepinephrine
,1493849,half life,"Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and 18 min, and the elimination half life ranged between 0.25 and 2.5 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),min,0.4 and 18,174457,DB00368,Norepinephrine
,1493849,elimination half life,"Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and 18 min, and the elimination half life ranged between 0.25 and 2.5 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),h,0.25 and 2.5,174458,DB00368,Norepinephrine
,1493849,volume of distribution (Vss),"The volume of distribution (Vss) was 74 l, (range 26 to 127 l).",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),l,74,174459,DB00368,Norepinephrine
,1493849,Total plasma clearance,"Total plasma clearance was 117 l.h-1, which exceeds the hepatic plasma flow.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),[l] / [h],117,174460,DB00368,Norepinephrine
,1493849,half life,"The data also suggested the existence of a slower elimination phase, with a half life of 13 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),h,13,174461,DB00368,Norepinephrine
,15545306,plasma t(max),"DOV 216,303 was rapidly absorbed (plasma t(max) of 0.7-1.2 hours and t(1/2) of 3.3-4.4 hours), with dose-proportional C(max) and AUC values.","DOV 216,303, a ""triple"" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545306/),h,0.7-1.2,174558,DB00368,Norepinephrine
,15545306,t(1/2),"DOV 216,303 was rapidly absorbed (plasma t(max) of 0.7-1.2 hours and t(1/2) of 3.3-4.4 hours), with dose-proportional C(max) and AUC values.","DOV 216,303, a ""triple"" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545306/),h,3.3-4.4,174559,DB00368,Norepinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,12.0,176883,DB00368,Norepinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,10.7,176884,DB00368,Norepinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,11.4,176885,DB00368,Norepinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,16.2,176886,DB00368,Norepinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,16,176887,DB00368,Norepinephrine
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1000,176980,DB00368,Norepinephrine
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1047,176981,DB00368,Norepinephrine
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],44,176982,DB00368,Norepinephrine
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],55,176983,DB00368,Norepinephrine
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],63,177505,DB00368,Norepinephrine
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],108,177506,DB00368,Norepinephrine
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],158,177507,DB00368,Norepinephrine
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],146,177508,DB00368,Norepinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.111,179686,DB00368,Norepinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.117,179687,DB00368,Norepinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,24,179688,DB00368,Norepinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,32,179689,DB00368,Norepinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.035,179690,DB00368,Norepinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.036,179691,DB00368,Norepinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,8,179692,DB00368,Norepinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,9,179693,DB00368,Norepinephrine
,9252564,Pulmonary spillover,"Pulmonary spillover of norepinephrine into the circulation was similar in 1-h (79 +/- 26 ng.min-1.kg-1) and 4-h (82 +/- 18 ng.min-1.kg-1) lambs, and this comprised 27 +/- 8 and 42 +/- 8% of total body norepinephrine spillover, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),[ng] / [kg·min],79,179694,DB00368,Norepinephrine
,9252564,Pulmonary spillover,"Pulmonary spillover of norepinephrine into the circulation was similar in 1-h (79 +/- 26 ng.min-1.kg-1) and 4-h (82 +/- 18 ng.min-1.kg-1) lambs, and this comprised 27 +/- 8 and 42 +/- 8% of total body norepinephrine spillover, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),[ng] / [kg·min],82,179695,DB00368,Norepinephrine
,9252564,Pulmonary spillover,"Pulmonary spillover of norepinephrine into the circulation was similar in 1-h (79 +/- 26 ng.min-1.kg-1) and 4-h (82 +/- 18 ng.min-1.kg-1) lambs, and this comprised 27 +/- 8 and 42 +/- 8% of total body norepinephrine spillover, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,27,179696,DB00368,Norepinephrine
,9252564,spillover,"Pulmonary epinephrine spillover was not detectable at 1 h, but it occurred in all 4-h lambs, averaging 4.7 +/- 0.8 ng.min-1.kg-1 or 20 +/- 6% of epinephrine total body spillover.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),[ng] / [kg·min],4.7,179697,DB00368,Norepinephrine
,9252564,spillover,"Pulmonary epinephrine spillover was not detectable at 1 h, but it occurred in all 4-h lambs, averaging 4.7 +/- 0.8 ng.min-1.kg-1 or 20 +/- 6% of epinephrine total body spillover.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,20,179698,DB00368,Norepinephrine
,20195828,absolute bioavailability,The absolute bioavailability of sibutramine was only about 7%.,Enantioselective pharmacokinetics of sibutramine in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20195828/),%,7,180124,DB00368,Norepinephrine
,12404320,t1/2,It is rapidly and extensively absorbed and almost completely eliminated after 12 h (t1/2 approx. 8 h).,Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404320/),h,8,180406,DB00368,Norepinephrine
>,12404320,bioavailable,Milnacipran is highly bioavailable (>85 per cent) and its metabolism does not involve the cytochrome P450 enzyme system.,Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404320/),%,85,180407,DB00368,Norepinephrine
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],0.3 to 97.3,181080,DB00368,Norepinephrine
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],6.7,181081,DB00368,Norepinephrine
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],402.8,181082,DB00368,Norepinephrine
,8541435,total dose,Over a period of 69.2 +/- 39.8 min during resection of the tumor the total dose was 7017 +/- 12433 micrograms.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),μg,7017,181083,DB00368,Norepinephrine
,24576769,clearance,"Following intravenous administration, JP-49b was found to have a rapid clearance (36±5.8L/h/kg), high volume of distribution (244±51.5L/kg) and a terminal half-life of 4.8±1.6h.",A sensitive and fast LC-MS/MS method for determination of β-receptor agonist JP-49b: application to a pharmacokinetic study in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24576769/),[l] / [h·kg],36,182676,DB00368,Norepinephrine
,24576769,volume of distribution,"Following intravenous administration, JP-49b was found to have a rapid clearance (36±5.8L/h/kg), high volume of distribution (244±51.5L/kg) and a terminal half-life of 4.8±1.6h.",A sensitive and fast LC-MS/MS method for determination of β-receptor agonist JP-49b: application to a pharmacokinetic study in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24576769/),[l] / [kg],244,182677,DB00368,Norepinephrine
,24576769,terminal half-life,"Following intravenous administration, JP-49b was found to have a rapid clearance (36±5.8L/h/kg), high volume of distribution (244±51.5L/kg) and a terminal half-life of 4.8±1.6h.",A sensitive and fast LC-MS/MS method for determination of β-receptor agonist JP-49b: application to a pharmacokinetic study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24576769/),h,4.8,182678,DB00368,Norepinephrine
,18582256,maximum diltiazem concentration,The maximum diltiazem concentration (577 microg.l(-1)) was recorded 7 h post ingestion which was followed by an erratic and prolonged elimination phase.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),[μg] / [l],577,184005,DB00368,Norepinephrine
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,19.4,184006,DB00368,Norepinephrine
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,15.1,184007,DB00368,Norepinephrine
,8531509,relative bioavailability,"The relative bioavailability of the tablet formulation after administration of 16 mg DL-oxyfedrine*HCl, based on the metabolite norephedrine*HCl was for AUC: 85.37% within a 90% confidence interval of 69.29-105.17% and for Cmax: 78.79% within a 90% confidence interval of 59.19-104.90%.",Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531509/),%,85.37,185079,DB00368,Norepinephrine
,8531509,relative bioavailability,"The relative bioavailability of the tablet formulation after administration of 16 mg DL-oxyfedrine*HCl, based on the metabolite norephedrine*HCl was for AUC: 85.37% within a 90% confidence interval of 69.29-105.17% and for Cmax: 78.79% within a 90% confidence interval of 59.19-104.90%.",Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531509/),%,78.79,185080,DB00368,Norepinephrine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],8.0,185266,DB00368,Norepinephrine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],2.1,185267,DB00368,Norepinephrine
,2357862,t[24],"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),,2.4,185268,DB00368,Norepinephrine
,10664922,oral clearance,"The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively.","Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664922/),[l] / [h],114,186115,DB00368,Norepinephrine
,10664922,apparent volume of distribution,"The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively.","Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664922/),l,1943,186116,DB00368,Norepinephrine
,10664922,half-life,"The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively.","Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664922/),h,12.5,186117,DB00368,Norepinephrine
,9331518,relative bioavailability,The relative bioavailability of selegiline was slightly reduced (by 29%; p = 0.008) when citalopram was coadministered compared with selegiline alone.,Lack of adverse interactions between concomitantly administered selegiline and citalopram. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331518/),,29,188189,DB00368,Norepinephrine
,7619663,critical flicker fusion threshold,"4. Only buspirone reduced total reaction time and increased critical flicker fusion threshold measured 12 h after the evening dose and these effects were correlated with the residual plasma 1PP concentration which was higher on buspirone than on ipsapirone (2.76 micrograms l-1, 95% CI:1.3-4.22 vs 0.65 microgram l-1, 95% CI: 0.32-0.98, P = 0.006).",Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),[μg] / [l],2.76,188197,DB00368,Norepinephrine
,7619663,AUC ipsapirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,6.45,188198,DB00368,Norepinephrine
,7619663,AUC buspirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,0.076,188199,DB00368,Norepinephrine
,24076172,K(i),"Previous studies have shown that compound 1 displayed high affinity towards histamine H3 receptor (H3R), (human (h-H3R), K(i)=8.6 nM, rhesus monkey (rh-H3R), K(i)=1.2 nM, and rat (r-H3R), K(i)=16.5 nM), but exhibited high affinity for hERG channel.","Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076172/),nM,8.6,188739,DB00368,Norepinephrine
,24076172,K(i),"Previous studies have shown that compound 1 displayed high affinity towards histamine H3 receptor (H3R), (human (h-H3R), K(i)=8.6 nM, rhesus monkey (rh-H3R), K(i)=1.2 nM, and rat (r-H3R), K(i)=16.5 nM), but exhibited high affinity for hERG channel.","Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076172/),nM,1.2,188740,DB00368,Norepinephrine
,24076172,K(i),"Previous studies have shown that compound 1 displayed high affinity towards histamine H3 receptor (H3R), (human (h-H3R), K(i)=8.6 nM, rhesus monkey (rh-H3R), K(i)=1.2 nM, and rat (r-H3R), K(i)=16.5 nM), but exhibited high affinity for hERG channel.","Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076172/),nM,16.5,188741,DB00368,Norepinephrine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,21.5,189217,DB00368,Norepinephrine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,12.2,189218,DB00368,Norepinephrine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,15.1,189219,DB00368,Norepinephrine
,9190324,half-life,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,5 to 7,190044,DB00368,Norepinephrine
,9190324,time to peak plasma concentration,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,3.1,190045,DB00368,Norepinephrine
,9190324,plasma protein binding,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),%,20,190046,DB00368,Norepinephrine
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,8.8,190327,DB00368,Norepinephrine
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,24.0,190328,DB00368,Norepinephrine
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,63,190329,DB00368,Norepinephrine
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,75,190330,DB00368,Norepinephrine
,7519866,maximum enzyme inhibition (IC50),"4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).","Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519866/),[μg] / [l],100,192781,DB00368,Norepinephrine
,7519866,IC50,"4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).","Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519866/),[μg] / [l],100,192782,DB00368,Norepinephrine
,7519866,IC50,"4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).","Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519866/),[μg] / [l],400,192783,DB00368,Norepinephrine
below,18779378,Plasma concentrations,Plasma concentrations declined below 1.0 microg/L within 30 minutes of cessation of infusion.,"Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779378/),[μg] / [l],1.0,192951,DB00368,Norepinephrine
,9743392,elimination half-lives,"The pharmacokinetics of atipamezole were linear, and elimination half-lives for both drugs were approximately 2 h.",Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743392/),h,2,193123,DB00368,Norepinephrine
,21171669,Elimination half-lives,Elimination half-lives ranged from 18.1 to 25.7 hours for etamicastat and 6.7 to 22.5 hours for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),h,18.1 to 25.7,195575,DB00368,Norepinephrine
,21171669,Elimination half-lives,Elimination half-lives ranged from 18.1 to 25.7 hours for etamicastat and 6.7 to 22.5 hours for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),h,6.7 to 22.5,195576,DB00368,Norepinephrine
,21171669,observed accumulation ratio,The mean observed accumulation ratio was 1.3-1.9 for etamicastat and 1.3-1.6 for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),,1.3-1.9,195577,DB00368,Norepinephrine
,21171669,observed accumulation ratio,The mean observed accumulation ratio was 1.3-1.9 for etamicastat and 1.3-1.6 for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),,1.3-1.6,195578,DB00368,Norepinephrine
,26916207,steady-state brain extracellular fluid/plasma unbound concentration ratio,"The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry.","Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26916207/),,1.9,196043,DB00368,Norepinephrine
,26916207,steady-state brain extracellular fluid/plasma unbound concentration ratio,"The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry.","Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26916207/),,1.7,196044,DB00368,Norepinephrine
,4072931,fractional my,The mean fractional myocardial thallium clearance was lower (0.47 +/- 0.03 [+/- standard error of the mean]) for the stenosis zone than for the no-stenosis zone (0.57 +/- 0.03) (p less than 0.0001).,Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),,0.47,196189,DB00368,Norepinephrine
,4072931,fractional my,The mean fractional myocardial thallium clearance was lower (0.47 +/- 0.03 [+/- standard error of the mean]) for the stenosis zone than for the no-stenosis zone (0.57 +/- 0.03) (p less than 0.0001).,Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),,0.57,196190,DB00368,Norepinephrine
,4072931,stress,"The stress blood flow ratio (stenosis/no-stenosis zone = 0.27 +/- 0.06) was significantly lower than the final thallium activity ratio (0.68 +/- 0.07) (p less than 0.001), consistent with thallium redistribution occurring over the 3-hour period.",Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),,0.27,196191,DB00368,Norepinephrine
,4072931,blood flow ratio,"The stress blood flow ratio (stenosis/no-stenosis zone = 0.27 +/- 0.06) was significantly lower than the final thallium activity ratio (0.68 +/- 0.07) (p less than 0.001), consistent with thallium redistribution occurring over the 3-hour period.",Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),,0.27,196192,DB00368,Norepinephrine
,4072931,activity ratio,"The stress blood flow ratio (stenosis/no-stenosis zone = 0.27 +/- 0.06) was significantly lower than the final thallium activity ratio (0.68 +/- 0.07) (p less than 0.001), consistent with thallium redistribution occurring over the 3-hour period.",Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),,0.68,196193,DB00368,Norepinephrine
,4072931,final decay constant,"Myocardial thallium activity in the stenosis zone peaked in a mean of 2.2 minutes, then washed out biexponentially with a final decay constant of 0.0035 +/- 0.0005 min-1.",Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),1/[min],0.0035,196194,DB00368,Norepinephrine
,4072931,final decay constant,"Myocardial thallium activity in the no-stenosis zone peaked within 1 minute in all dogs, then washed out biexponentially, with a final decay constant of 0.0043 +/- 0.0003 (p less than 0.001 compared with stenosis zone).",Myocardial kinetics of thallium-201 after stress in normal and perfusion-reduced canine myocardium. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4072931/),,0.0043,196195,DB00368,Norepinephrine
,21925241,K(i),"Competitive radioligand binding assays were performed using cells expressing the human dopamine (DA) transporter (hDAT), the human serotonin (5-HT) transporter (hSERT), and the human norepinephrine (NE) transporter (hNET) with K(i) values for TP1 of 190 nM, 2076 nM, and 1023 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,190,197720,DB00368,Norepinephrine
,21925241,K(i),"Competitive radioligand binding assays were performed using cells expressing the human dopamine (DA) transporter (hDAT), the human serotonin (5-HT) transporter (hSERT), and the human norepinephrine (NE) transporter (hNET) with K(i) values for TP1 of 190 nM, 2076 nM, and 1023 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,2076,197721,DB00368,Norepinephrine
,21925241,K(i),"Competitive radioligand binding assays were performed using cells expressing the human dopamine (DA) transporter (hDAT), the human serotonin (5-HT) transporter (hSERT), and the human norepinephrine (NE) transporter (hNET) with K(i) values for TP1 of 190 nM, 2076 nM, and 1023 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,1023,197722,DB00368,Norepinephrine
,21925241,IC(50),"Uptake assays were performed with IC(50) values for TP1 of 712 nM, 521 nM, and 628 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,712,197723,DB00368,Norepinephrine
,21925241,IC(50),"Uptake assays were performed with IC(50) values for TP1 of 712 nM, 521 nM, and 628 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,521,197724,DB00368,Norepinephrine
,21925241,IC(50),"Uptake assays were performed with IC(50) values for TP1 of 712 nM, 521 nM, and 628 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,628,197725,DB00368,Norepinephrine
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB00368,Norepinephrine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB00368,Norepinephrine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB00368,Norepinephrine
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB00368,Norepinephrine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB00368,Norepinephrine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB00368,Norepinephrine
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB00368,Norepinephrine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB00368,Norepinephrine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB00368,Norepinephrine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB00368,Norepinephrine
,20220040,peak increase,"The peak increase in plasma NE (0.57 ± 0.11 nmol/L) averaged less than 1/15,000 th that in L-DOPS and less than 1/35th that in DHPG+DHMA.",Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20220040/),[nM] / [l],0.57,202503,DB00368,Norepinephrine
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.2 × 10(-5),203539,DB00368,Norepinephrine
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.1 × 10(-6 ),203540,DB00368,Norepinephrine
greater,25915108,efflux ratio,"The secretory efflux ratio in MDCK-II cells overexpressing human P-gp showed an efflux ratio greater than 2, for both compounds, which was significantly decreased by elacridar.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),,2,203541,DB00368,Norepinephrine
,25915108,plasma free fraction,"Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15.5%), which may explain its effects upon peripheral DBH and catecholamine levels.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),%,15.5,203542,DB00368,Norepinephrine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],36.5,204004,DB00368,Norepinephrine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],73.8,204005,DB00368,Norepinephrine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],207,204006,DB00368,Norepinephrine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],5.81,204007,DB00368,Norepinephrine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],5.51,204008,DB00368,Norepinephrine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],3.91,204009,DB00368,Norepinephrine
,2441162,terminal half-life (t1/2),The pharmacokinetics of S-9780 fitted a three-compartment model with a terminal half-life (t1/2) of 31 h.,"Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441162/),h,31,204335,DB00368,Norepinephrine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],3.8,205627,DB00368,Norepinephrine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],2.5,205628,DB00368,Norepinephrine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,3.3,205629,DB00368,Norepinephrine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,5.9,205630,DB00368,Norepinephrine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],1.5,205631,DB00368,Norepinephrine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],2.1,205632,DB00368,Norepinephrine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,26.3,205633,DB00368,Norepinephrine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,25.0,205634,DB00368,Norepinephrine
,10454044,systemic clearances,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[ml] / [kg·min],146,205635,DB00368,Norepinephrine
,33482315,Tmax,Ammoxetine was well absorbed after oral administration with Tmax reached in 5.0-6.0 h.,"First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33482315/),h,5.0-6.0,205817,DB00368,Norepinephrine
<,33482315,urinary excretion,The low extent of urinary excretion of ammoxetine (< 2%) indicated it is undergoing extensive metabolism.,"First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33482315/),%,2,205818,DB00368,Norepinephrine
,21647215,ED50,"In the complete Freund's adjuvant (CFA) rat model of inflammatory pain, CR4056 was found to be orally active (ED50 = 5.8 mg/kg, by mouth [p.o.]).","Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21647215/),[mg] / [kg],5.8,205897,DB00368,Norepinephrine
,21647215,ED50,"In the acute capsaicin model, CR4056 completely blocked mechanical hyperalgesia in the injured hind paw (ED50 = 4.1 mg/kg, p.o.; ED100 = 17.9 mg/kg, p.o.).","Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21647215/),[mg] / [kg],4.1,205898,DB00368,Norepinephrine
,21647215,ED100,"In the acute capsaicin model, CR4056 completely blocked mechanical hyperalgesia in the injured hind paw (ED50 = 4.1 mg/kg, p.o.; ED100 = 17.9 mg/kg, p.o.).","Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21647215/),[mg] / [kg],17.9,205899,DB00368,Norepinephrine
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],64,207462,DB00368,Norepinephrine
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],27,207463,DB00368,Norepinephrine
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],47,207464,DB00368,Norepinephrine
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],34,207465,DB00368,Norepinephrine
,7978186,peak plasma concentrations,The peak plasma concentrations were P 10.6 +/- 1.5 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,10.6,207603,DB00368,Norepinephrine
,7978186,M,ml-1 and M 12.4 +/- 2.6 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,12.4,207604,DB00368,Norepinephrine
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,15,207605,DB00368,Norepinephrine
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,50,207606,DB00368,Norepinephrine
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,25,207607,DB00368,Norepinephrine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.973,209164,DB00368,Norepinephrine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.136,209165,DB00368,Norepinephrine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.041,209166,DB00368,Norepinephrine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,38,209167,DB00368,Norepinephrine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,53,209168,DB00368,Norepinephrine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,75,209169,DB00368,Norepinephrine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,2.72,209170,DB00368,Norepinephrine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,1.22,209171,DB00368,Norepinephrine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.794,209172,DB00368,Norepinephrine
,26794682,tmax,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,10-12,213346,DB00368,Norepinephrine
,26794682,elimination (t1/2,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,47-77,213347,DB00368,Norepinephrine
,26150694,plasma protein binding,Levomilnacipran was widely distributed with low plasma protein binding (22%).,"Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150694/),%,22,215059,DB00368,Norepinephrine
,29427845,zeta potential,"Optimized microemulsion (D1) showed spherical droplets with mean diameter of 35.40 ± 3.11 nm, PDI of 0.170 and zeta potential values of -25.8 mV.",Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427845/),m,25.8,215515,DB00368,Norepinephrine
greater,29427845,transmit,"Formulation showed good transmittance (greater than 99%), viscosity (0.205 Pa s) and refractive index (1.43 ± 0.01).",Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427845/),%,99,215516,DB00368,Norepinephrine
,29427845,viscosity,"Formulation showed good transmittance (greater than 99%), viscosity (0.205 Pa s) and refractive index (1.43 ± 0.01).",Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427845/),pa·s,0.205,215517,DB00368,Norepinephrine
,33892588,peak concentration (Cmax),"Results revealed detectable plasma concentrations in only 2 of 7 birds (29%), and the bird with the highest plasma levels had a peak concentration (Cmax) of 143 ng/mL and a half-life (T 1/2) of 24.8 minutes.",Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892588/),[ng] / [ml],143,216544,DB00368,Norepinephrine
,33892588,half-life (T 1/2),"Results revealed detectable plasma concentrations in only 2 of 7 birds (29%), and the bird with the highest plasma levels had a peak concentration (Cmax) of 143 ng/mL and a half-life (T 1/2) of 24.8 minutes.",Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892588/),min,24.8,216545,DB00368,Norepinephrine
,32856281,terminal half-life,"The terminal half-life was 30-40 h, resulting in sustained drug concentrations for the entire 24-h dosing interval at steady state.","Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856281/),h,30-40,216558,DB00368,Norepinephrine
,15505444,BIS,"In a randomized, prospective design, 20 patients received propofol at a target concentration of 3 microg/ml, whereas in 20 patients propofol was titrated to maintain a BIS value of 40-50.",Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505444/),,40-50,216645,DB00368,Norepinephrine
,19622169,half-life,The corresponding half-life was 3.5 minutes.,Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19622169/),min,3.5,220582,DB00368,Norepinephrine
,10780953,VO(2 max),"Seven fit male subjects (26 +/- 2 yr, body mass index 23 +/- 0.5 kg/m(2), VO(2 max) 65 +/- 5 ml x kg(-1) x min(-1)) underwent 40 min of postabsorptive cycle ergometer exercise (145 +/- 14 W) once without [control (CON)] and once with Epi infusion [EPI (0.1 microg x kg(-1) x min(-1))] from 30 to 40 min.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[ml] / [kg·min],65,221477,DB00368,Norepinephrine
,10780953,Epi levels,"Epi levels reached 9.4 +/- 0.8 nM (20x rest, 10x CON).",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),nM,9.4,221478,DB00368,Norepinephrine
,10780953,R(a),R(a) increased approximately 70% to 3.75 +/- 0.53 in CON but to 8.57 +/- 0.58 mg x kg(-1) x min(-1) in EPI (P < 0.001).,Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[mg] / [kg·min],3.75,221479,DB00368,Norepinephrine
,10780953,R(a),R(a) increased approximately 70% to 3.75 +/- 0.53 in CON but to 8.57 +/- 0.58 mg x kg(-1) x min(-1) in EPI (P < 0.001).,Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[mg] / [kg·min],8.57,221480,DB00368,Norepinephrine
,10780953,peak R(d),"In EPI, peak R(d) (5.55 +/- 0.54 vs.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,5.55,221481,DB00368,Norepinephrine
,10780953,R(a)-to-R(d),"The R(a)-to-R(d) imbalance in EPI caused hyperglycemia (7.12 +/- 0.22 vs. 5.59 +/- 0.22 mM, P = 0.001) until minute 60 of recovery.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,7,221482,DB00368,Norepinephrine
,10780953,R(a)-to-R(d),"The R(a)-to-R(d) imbalance in EPI caused hyperglycemia (7.12 +/- 0.22 vs. 5.59 +/- 0.22 mM, P = 0.001) until minute 60 of recovery.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,5,221483,DB00368,Norepinephrine
,22237133,flow rate of the mobile phase,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),[μl] / [min],250,222850,DB00368,Norepinephrine
,22237133,retention times,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),min,0.9,222851,DB00368,Norepinephrine
,22237133,retention times,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),min,1.0,222852,DB00368,Norepinephrine
,7460470,plasma,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.33,223174,DB00368,Norepinephrine
,7460470,plasma,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.08,223175,DB00368,Norepinephrine
,7460470,clearance,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.33,223176,DB00368,Norepinephrine
,7460470,clearance,"Desipramine reduced the plasma norepinephrine clearance by approximately 20%, from 1.33 +/- 0.22 to 1.08 +/- 0.19 l/m2/min (p less than 0.01).",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[l] / [m2·min],1.08,223177,DB00368,Norepinephrine
,7460470,rate of spillover,"Desipramine also reduced the rate of spillover of norepinephrine to plasma, 0.27 +/- 0.07 to 0.15 +/- 0.04 micrograms/m2/min, leaving the plasma norepinephrine concentration unchanged.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[μg] / [m2·min],0.27,223178,DB00368,Norepinephrine
,7460470,rate of spillover,"Desipramine also reduced the rate of spillover of norepinephrine to plasma, 0.27 +/- 0.07 to 0.15 +/- 0.04 micrograms/m2/min, leaving the plasma norepinephrine concentration unchanged.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),[μg] / [m2·min],0.15,223179,DB00368,Norepinephrine
,7460470,half-time of the rapid-removal phase (t1 1/2),"Disappearance of tritiated norepinephrine from plasma, after infusion to steady state, was biexponential, with half-time of the rapid-removal phase (t1 1/2) = 2.0 +/- 0.4 min and half-time of the second exponential (t2 1/2) = 34 +/- 10 min.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),min,2.0,223180,DB00368,Norepinephrine
,7460470,half-time of the second exponential (t2 1/2),"Disappearance of tritiated norepinephrine from plasma, after infusion to steady state, was biexponential, with half-time of the rapid-removal phase (t1 1/2) = 2.0 +/- 0.4 min and half-time of the second exponential (t2 1/2) = 34 +/- 10 min.",Effect of norepinephrine uptake blockers on norepinephrine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460470/),min,34,223181,DB00368,Norepinephrine
,703854,ED50,"Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg).",Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/703854/),[mmoles] / [kg],0.057,226624,DB00368,Norepinephrine
,703854,ED50,"Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg).",Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/703854/),[mmoles] / [kg],0.117,226625,DB00368,Norepinephrine
≈,29172829,oral bioavailability,Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism.,Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172829/),%,50,227314,DB00368,Norepinephrine
,29172829,percentage relative bioavailability,The percentage relative bioavailability of DH from F2 was found to be 296.39%.,Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172829/),%,296.39,227315,DB00368,Norepinephrine
,14650359,bioavailability,Following oral administration the bioavailability of tramadol is high (70-90%) and with new slow release preparations twice daily administration enables effective pain control.,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,70-90,227851,DB00368,Norepinephrine
,14650359,plasma protein binding,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,20,227852,DB00368,Norepinephrine
,14650359,apparent volume of distribution,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[l] / [kg],3,227853,DB00368,Norepinephrine
,14650359,Elimination half-lives,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),h,4.5 and 9.5,227854,DB00368,Norepinephrine
,14650359,total plasma clearance,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[ml] / [min],600,227855,DB00368,Norepinephrine
,1797482,bioavailability,The estimated bioavailability of subcutaneous insulin was 103.0 +/- 10.5% of the injected dose.,Intravenous insulin infusion to simulate subcutaneous absorption. Bioavailability and metabolic sequelae. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797482/),%,103.0,228476,DB00368,Norepinephrine
,26597180,apparent half-life,"In an ADHD population treated with dasotraline 4 or 8 mg/day, dasotraline was characterized by a mean apparent half-life of 47 h and plasma concentrations reached steady-state by 10 days of dosing.",Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597180/),h,47,231149,DB00368,Norepinephrine
∼,25019201,tmax,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,2,231162,DB00368,Norepinephrine
,25019201,plasma t1/2,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,4 - 6,231163,DB00368,Norepinephrine
,662597,half-life,"Observation of plama levels showed that the half-life propanolol in the case of overdose is prolonged: 8.6 hours in this case, with a maximum plasma level of 1536 ng/ml.",[Deliberate self-overdose with propranolol. Changes in serum levels (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/662597/),h,8.6,231302,DB00368,Norepinephrine
,662597,maximum plasma level,"Observation of plama levels showed that the half-life propanolol in the case of overdose is prolonged: 8.6 hours in this case, with a maximum plasma level of 1536 ng/ml.",[Deliberate self-overdose with propranolol. Changes in serum levels (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/662597/),[ng] / [ml],1536,231303,DB00368,Norepinephrine
,18093252,time of peak nifedipine concentrations,"Plasma NE was higher in the Coracten- (480 +/- 38.3 pg ml(-1)) than N-GITS-treated patients (343 +/- 75.0 pg ml(-1)) at the time of peak nifedipine concentrations (4 and 5 h, respectively) and their change from baseline was significantly (P = 0.0046) different.",Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18093252/),h,4,233599,DB00368,Norepinephrine
,18093252,time of peak nifedipine concentrations,"Plasma NE was higher in the Coracten- (480 +/- 38.3 pg ml(-1)) than N-GITS-treated patients (343 +/- 75.0 pg ml(-1)) at the time of peak nifedipine concentrations (4 and 5 h, respectively) and their change from baseline was significantly (P = 0.0046) different.",Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18093252/),h,5,233600,DB00368,Norepinephrine
,15747778,Concentrations,"Concentrations of plasma corticosterone before gavage of the corticosterone-drinking rats (47.61 +/- 1.13 ng/mL) were lower than the water (418.47 +/- 1.13 ng/mL) or the ethanol rats (383.71 +/- 1.13 ng/mL, P < 0.0001).","Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747778/),[ng] / [ml],47.61,235784,DB00368,Norepinephrine
,15747778,Concentrations,"Concentrations of plasma corticosterone before gavage of the corticosterone-drinking rats (47.61 +/- 1.13 ng/mL) were lower than the water (418.47 +/- 1.13 ng/mL) or the ethanol rats (383.71 +/- 1.13 ng/mL, P < 0.0001).","Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747778/),[ng] / [ml],418.47,235785,DB00368,Norepinephrine
,15747778,Concentrations,"Concentrations of plasma corticosterone before gavage of the corticosterone-drinking rats (47.61 +/- 1.13 ng/mL) were lower than the water (418.47 +/- 1.13 ng/mL) or the ethanol rats (383.71 +/- 1.13 ng/mL, P < 0.0001).","Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747778/),[ng] / [ml],383.71,235786,DB00368,Norepinephrine
,7197974,half-life,"In the rat the absorption proceeds with a half-life of 11 min, after a lag phase of 6 min.",Pharmacokinetics of amezinium in rat and dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),min,11,237039,DB00368,Norepinephrine
,7197974,lag phase,"In the rat the absorption proceeds with a half-life of 11 min, after a lag phase of 6 min.",Pharmacokinetics of amezinium in rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),min,6,237040,DB00368,Norepinephrine
,7197974,lag phase,"In the dog, the lag phase is 30-40 min, after which the compound is absorbed with a half-life of 30 min or less.",Pharmacokinetics of amezinium in rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),min,30-40,237041,DB00368,Norepinephrine
,7197974,half-life,"In the dog, the lag phase is 30-40 min, after which the compound is absorbed with a half-life of 30 min or less.",Pharmacokinetics of amezinium in rat and dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),min,30,237042,DB00368,Norepinephrine
,7197974,terminal half-life t 1/2 (beta),"From plasma level curves the terminal half-life t 1/2 (beta) in the rat was found to be 17 h and 21 h after i.v. and p.o. administration, respectively; blood level data and urinary excretion data in the case of the dog gave 5 1/2 (beta) values between 11 h and 20 h.",Pharmacokinetics of amezinium in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),h,17,237043,DB00368,Norepinephrine
,7197974,terminal half-life t 1/2 (beta),"From plasma level curves the terminal half-life t 1/2 (beta) in the rat was found to be 17 h and 21 h after i.v. and p.o. administration, respectively; blood level data and urinary excretion data in the case of the dog gave 5 1/2 (beta) values between 11 h and 20 h.",Pharmacokinetics of amezinium in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),h,21,237044,DB00368,Norepinephrine
,7197974,5 1/2 (beta),"From plasma level curves the terminal half-life t 1/2 (beta) in the rat was found to be 17 h and 21 h after i.v. and p.o. administration, respectively; blood level data and urinary excretion data in the case of the dog gave 5 1/2 (beta) values between 11 h and 20 h.",Pharmacokinetics of amezinium in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),h,11,237045,DB00368,Norepinephrine
,7197974,5 1/2 (beta),"From plasma level curves the terminal half-life t 1/2 (beta) in the rat was found to be 17 h and 21 h after i.v. and p.o. administration, respectively; blood level data and urinary excretion data in the case of the dog gave 5 1/2 (beta) values between 11 h and 20 h.",Pharmacokinetics of amezinium in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197974/),h,20,237046,DB00368,Norepinephrine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.1,237702,DB00368,Norepinephrine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.5,237703,DB00368,Norepinephrine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.5,237704,DB00368,Norepinephrine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.0,237705,DB00368,Norepinephrine
,23623756,Tmax,"Median Tmax was similar for all groups (range, 6-9 hours).","An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23623756/),h,6-9,237802,DB00368,Norepinephrine
,19433973,first-order elimination half-life,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),h,11.3,239277,DB00368,Norepinephrine
,19433973,clearance,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),[ml] / [min],56.2,239278,DB00368,Norepinephrine
,11420889,Cmax,"Cmax in the elderly was 271 +/- 86 ng/ml, compared with 111 +/- 28 ng/ml in the young subjects after a single 4-mg dose, although in both groups Cmax was observed after 2 h.","Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[ng] / [ml],271,240422,DB00368,Norepinephrine
,11420889,Cmax,"Cmax in the elderly was 271 +/- 86 ng/ml, compared with 111 +/- 28 ng/ml in the young subjects after a single 4-mg dose, although in both groups Cmax was observed after 2 h.","Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[ng] / [ml],111,240423,DB00368,Norepinephrine
,11420889,AUC infinity,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[h·ng] / [ml],8345,240424,DB00368,Norepinephrine
,11420889,AUC infinity,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[h·ng] / [ml],2106,240425,DB00368,Norepinephrine
,11420889,t1/2,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),h,24,240426,DB00368,Norepinephrine
,11420889,t1/2,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),h,12,240427,DB00368,Norepinephrine
,24989060,CL/F,"Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively.",Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989060/),[l] / [h],79.7,241113,DB00368,Norepinephrine
,24989060,V d/F,"Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively.",Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989060/),l,"1,200",241114,DB00368,Norepinephrine
,24989060,half-life (t 1/2),"Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively.",Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989060/),h,10.4,241115,DB00368,Norepinephrine
>,20578835,specific activities,"In this study, specific activities of >1200 mCi/micromol for (123)I and >1600 mCi/micromol for (131)I have been achieved.","Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20578835/),[mci] / [μM],1200,243058,DB00368,Norepinephrine
>,20578835,specific activities,"In this study, specific activities of >1200 mCi/micromol for (123)I and >1600 mCi/micromol for (131)I have been achieved.","Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20578835/),[mci] / [μM],1600,243059,DB00368,Norepinephrine
,24347,half-time,"After infusion, the plasma norepinephrine concentration fell with a mean (+/-SD) half-time of 2.4 +/- 0.7 min.",Norepinephrine: hormone and neurotransmitter in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24347/),min,2.4,244207,DB00368,Norepinephrine
,24347,metabolic clearance rate,"The mean (+/-SD) norepinephrine metabolic clearance rate was 3,070 +/- 200 ml/min.",Norepinephrine: hormone and neurotransmitter in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24347/),[ml] / [min],"3,070",244208,DB00368,Norepinephrine
,24347,basal plasma,The calculated basal plasma norepinephrine production rate was 0.7 microgram/min.,Norepinephrine: hormone and neurotransmitter in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24347/),[μg] / [min],0.7,244209,DB00368,Norepinephrine
,6190484,biological half-life,"The intracerebral level of morphine was found to depend on the dose injected, and the biological half-life of the drug was estimated to be about 1 hr.",Direct correlation between level of morphine and its biochemical effect on monoamine systems in mouse brain. Evidence for involvement of dopaminergic neurons in the pharmacological action of acute morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6190484/),h,1,248070,DB00368,Norepinephrine
,1636772,clearance,"The NE clearance was lower in CHF than in the control group (CHF 1.25 +/- 0.13, controls 2.04 +/- 0.22 l.min-1.m-2; P = 0.009).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],1.25,250331,DB00368,Norepinephrine
,1636772,clearance,"The NE clearance was lower in CHF than in the control group (CHF 1.25 +/- 0.13, controls 2.04 +/- 0.22 l.min-1.m-2; P = 0.009).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],2.04,250332,DB00368,Norepinephrine
,1636772,clearance,"The ISO clearance was reduced similarly in CHF (CHF 0.90 +/- 0.09, controls 1.59 +/- 0.12 l.min-1.m-2; P less than 0.001).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],0.90,250333,DB00368,Norepinephrine
,1636772,clearance,"The ISO clearance was reduced similarly in CHF (CHF 0.90 +/- 0.09, controls 1.59 +/- 0.12 l.min-1.m-2; P less than 0.001).",Comparison of norepinephrine and isoproterenol clearance in congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1636772/),[l] / [(m)^2·min],1.59,250334,DB00368,Norepinephrine
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],485,250572,DB00368,Norepinephrine
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],283,250573,DB00368,Norepinephrine
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],181,250574,DB00368,Norepinephrine
,9951425,clearance,"Median clearance of L-NG-methylarginine averaged 485 mL/h/kg for the 1 and 2.5 mg/kg/h dosing cohorts combined but decreased to 283, 181, and 98 mL/h/kg for the 5, 10, and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],98,250575,DB00368,Norepinephrine
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],9 to,250576,DB00368,Norepinephrine
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],26,250577,DB00368,Norepinephrine
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],156,250578,DB00368,Norepinephrine
,9951425,renal clearance,"Median renal clearance was similar at 9 to 26 mL/h for the 1, 2.5, and 5 mg/kg/h dosing cohorts but increased to 156 and 284 mL/h for the 10 and 20 mg/kg/h dosing cohorts, respectively.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h],284,250579,DB00368,Norepinephrine
,9951425,steady-state volume of distribution,"Median steady-state volume of distribution was similar in all 5 dosing cohorts, averaging 0.66 to 0.82 L/kg.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[l] / [kg],0.66 to 0.82,250580,DB00368,Norepinephrine
,9951425,clearance,"The 80% decrease in clearance from 485 to 98 mL/h/kg with the increase in dose suggests that a predominant metabolic pathway(s) of L-NG-methylarginine, accounting for at least 80% of clearance, is becoming progressively saturable in association with L-NG-methylarginine infusion rates > or = 5 mg/kg/h.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],485,250581,DB00368,Norepinephrine
,9951425,clearance,"The 80% decrease in clearance from 485 to 98 mL/h/kg with the increase in dose suggests that a predominant metabolic pathway(s) of L-NG-methylarginine, accounting for at least 80% of clearance, is becoming progressively saturable in association with L-NG-methylarginine infusion rates > or = 5 mg/kg/h.",Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951425/),[ml] / [h·kg],98,250582,DB00368,Norepinephrine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,8.3,251826,DB00368,Norepinephrine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,2.1,251827,DB00368,Norepinephrine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,4.0,251828,DB00368,Norepinephrine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,2.5,251829,DB00368,Norepinephrine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.42,251830,DB00368,Norepinephrine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.70,251831,DB00368,Norepinephrine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.99,251832,DB00368,Norepinephrine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.84,251833,DB00368,Norepinephrine
,1587960,AUC,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [h·ml],16.2,251834,DB00368,Norepinephrine
,1587960,AUC,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [h·ml],16.6,251835,DB00368,Norepinephrine
exceeded,1587960,T1/2,"T1/2 values for the conventional formulation of clonidine exceeded 20 hours in all but one subject and were considerably longer than those in previous reports, including those of the authors, in which a less sensitive assay was used.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,20,251836,DB00368,Norepinephrine
,16303903,Half-life,"Half-life and volume of distribution are 12 hours and 1640 L, respectively.",Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303903/),h,12,252091,DB00368,Norepinephrine
,16303903,volume of distribution,"Half-life and volume of distribution are 12 hours and 1640 L, respectively.",Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303903/),l,1640,252092,DB00368,Norepinephrine
,3987180,elimination t1/2,"After intravenous nifedipine infusion, the elimination t1/2 was 106 +/- 24 minutes in controls and increased gradually across the groups to 230 +/- 94 minutes in the group with severe renal impairment.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),min,106,253059,DB00368,Norepinephrine
,3987180,elimination t1/2,"After intravenous nifedipine infusion, the elimination t1/2 was 106 +/- 24 minutes in controls and increased gradually across the groups to 230 +/- 94 minutes in the group with severe renal impairment.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),min,230,253060,DB00368,Norepinephrine
,3987180,volume of distribution at steady state,"In these same groups, the volume of distribution at steady state was 0.78 +/- 0.23 and 1.47 +/- 0.24 L/kg, but total systemic clearance did not differ.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),[l] / [kg],0.78,253061,DB00368,Norepinephrine
,3987180,volume of distribution at steady state,"In these same groups, the volume of distribution at steady state was 0.78 +/- 0.23 and 1.47 +/- 0.24 L/kg, but total systemic clearance did not differ.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),[l] / [kg],1.47,253062,DB00368,Norepinephrine
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],341,256101,DB00368,Norepinephrine
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],405,256102,DB00368,Norepinephrine
below,1672843,residual plasma concentration,"At a residual plasma concentration below 100 ng/ml, ST depression was not significantly improved 24 h after drug intake compared with placebo.","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),,100,256103,DB00368,Norepinephrine
,1672843,Maximum IS-5-MN plasma concentrations,Maximum IS-5-MN plasma concentrations at a mean of 445 +/- 116 ng/ml were reached after 5.8 +/- 2.9 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],445,256104,DB00368,Norepinephrine
,1672843,Beta-phase half-life of elimination,Beta-phase half-life of elimination was 9 +/- 3 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),h,9,256105,DB00368,Norepinephrine
,7315181,t 1/2 alpha,Elimination of dopamine from plasma after termination of infusion had a biphasic course with t 1/2 alpha around 1 min and t 1/2 beta about 9 min in both groups.,Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315181/),min,1,256330,DB00368,Norepinephrine
,7315181,t 1/2 beta,Elimination of dopamine from plasma after termination of infusion had a biphasic course with t 1/2 alpha around 1 min and t 1/2 beta about 9 min in both groups.,Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315181/),min,9,256331,DB00368,Norepinephrine
,20235455,terminal half-life,The terminal half-life of tramadol after intravenous dosing was 2.46 hours.,Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),h,2.46,256881,DB00368,Norepinephrine
,20235455,maximum plasma concentration,"The maximum plasma concentration, time of maximum plasma concentration, and terminal half life for tramadol after oral dosing were 2156.7 ng/ml, 3.75 hours, and 3.14 hours, respec vely.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),[ng] / [ml],2156.7,256882,DB00368,Norepinephrine
,20235455,time of maximum plasma concentration,"The maximum plasma concentration, time of maximum plasma concentration, and terminal half life for tramadol after oral dosing were 2156.7 ng/ml, 3.75 hours, and 3.14 hours, respec vely.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),h,3.75,256883,DB00368,Norepinephrine
,20235455,terminal half life,"The maximum plasma concentration, time of maximum plasma concentration, and terminal half life for tramadol after oral dosing were 2156.7 ng/ml, 3.75 hours, and 3.14 hours, respec vely.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),h,3.14,256884,DB00368,Norepinephrine
,20235455,oral bioavailability,"In addition, the oral bioavailability was 97.9%.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),%,97.9,256885,DB00368,Norepinephrine
,3428692,Whole body clearance,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[l] / [min],1.6,260300,DB00368,Norepinephrine
,3428692,Whole body clearance,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[l] / [min],1.7,260301,DB00368,Norepinephrine
,3428692,overall appearance rate,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],4.2,260302,DB00368,Norepinephrine
,3428692,overall appearance rate,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],2.6,260303,DB00368,Norepinephrine
,3428692,hepatic intestinal spillover rate,"The hepatic intestinal clearances of A, NA, and 3H-NA were not significantly different in patients and controls, but the estimated hepatic intestinal spillover rate of NA was 0.24 nmol/min in patients as compared with 0.0 nmol/min in controls (p less than 0.02).",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],0.24,260304,DB00368,Norepinephrine
,3428692,hepatic intestinal spillover rate,"The hepatic intestinal clearances of A, NA, and 3H-NA were not significantly different in patients and controls, but the estimated hepatic intestinal spillover rate of NA was 0.24 nmol/min in patients as compared with 0.0 nmol/min in controls (p less than 0.02).",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],0.0,260305,DB00368,Norepinephrine
,31578015,Peak anti-Xa,Peak anti-Xa was significantly higher in the IV group 0.42 (0.39-0.43) IU/mL than in the SC group 0.16 (0.09-0.18) IU/mL (p < 0.001).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [ml],0.42,261293,DB00368,Norepinephrine
,31578015,Peak anti-Xa,Peak anti-Xa was significantly higher in the IV group 0.42 (0.39-0.43) IU/mL than in the SC group 0.16 (0.09-0.18) IU/mL (p < 0.001).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [ml],0.16,261294,DB00368,Norepinephrine
,31578015,area under the curve (AUC),There was a trend towards higher area under the curve (AUC) of anti-Xa in the SC group 1.41 (0.41-1.80) IU/mL × h than in the IV group 1.04 (0.93-1.13) IU/mL × h (p = 0.08).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [h·ml],1.41,261295,DB00368,Norepinephrine
,31578015,area under the curve (AUC),There was a trend towards higher area under the curve (AUC) of anti-Xa in the SC group 1.41 (0.41-1.80) IU/mL × h than in the IV group 1.04 (0.93-1.13) IU/mL × h (p = 0.08).,Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),[iu] / [h·ml],1.04,261296,DB00368,Norepinephrine
,31578015,decrease half-life,"In the IV group, anti-Xa decrease half-life was 1.6 (1.4-2.0) h.",Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31578015/),h,1.6,261297,DB00368,Norepinephrine
,26681081,Volume of distribution,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [kg],0.48,261685,DB00368,Norepinephrine
,26681081,clearance,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [h·kg],0.0034,261686,DB00368,Norepinephrine
,26681081,half-life,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),h,93.7,261687,DB00368,Norepinephrine
,6807683,Clearance,"Clearance did not differ between the two groups: young 4.8 l/min (range 2.7-6.1), old 4.1 (range 2.6-8.2).",Noradrenaline release and clearance in relation to age and blood pressure in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6807683/),[l] / [min],4.8,261778,DB00368,Norepinephrine
,6807683,Clearance,"Clearance did not differ between the two groups: young 4.8 l/min (range 2.7-6.1), old 4.1 (range 2.6-8.2).",Noradrenaline release and clearance in relation to age and blood pressure in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6807683/),,4.1,261779,DB00368,Norepinephrine
,14749346,MAP,MAP increased significantly following NOR administration from 73.3 +/- 3.5 mmHg at baseline to 94.0 +/- 5.2 mmHg during infusion (P = 0.017).,Effect of norepinephrine on cefpirome tissue concentrations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749346/),mmhg,73.3,263789,DB00368,Norepinephrine
,14749346,MAP,MAP increased significantly following NOR administration from 73.3 +/- 3.5 mmHg at baseline to 94.0 +/- 5.2 mmHg during infusion (P = 0.017).,Effect of norepinephrine on cefpirome tissue concentrations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749346/),mmhg,94.0,263790,DB00368,Norepinephrine
,25116481,elimination half-life,Median maximum concentrations of BMS-820836 were observed at 4.0-5.5 h post-dose; estimated elimination half-life was 44-74 h.,"Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116481/),h,44-74,266329,DB00368,Norepinephrine
,25116481,occupancy,Striatal DAT occupancy ranged between 14 % and 35 % at 8 h post-dose with a slight decline at 24 h post-dose.,"Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116481/),%,14,266330,DB00368,Norepinephrine
,25116481,occupancy,Striatal DAT occupancy ranged between 14 % and 35 % at 8 h post-dose with a slight decline at 24 h post-dose.,"Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116481/),%,35,266331,DB00368,Norepinephrine
,7128667,initial lag time,"Following oral administration, the drug was absorbed rapidly after an initial lag time of 19-22 min and peak levels were reached between 2.4 and 2.9 h.",Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128667/),min,19-22,266977,DB00368,Norepinephrine
,7128667,half-life of the elimination phase,Post-peak plasma concentration declined in a monoexponential manner and the half-life of the elimination phase ranged from 9.0 to 15.1 h.,Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128667/),h,9.0 to 15.1,266978,DB00368,Norepinephrine
,12607628,elimination half-life,BP is rapidly absorbed after oral administration and demonstrates biphasic elimination with an elimination half-life of 11 - 14 hours.,Bupropion: pharmacological and clinical profile in smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607628/),h,11 - 14,271070,DB00368,Norepinephrine
,2687065,plasma clearance,In patients with (n = 8) and without (n = 8) neuropathy forearm venous plasma noradrenaline and adrenaline concentrations as well as plasma clearance of adrenaline based on arterial sampling (1.7 vs 2.1 l/min) were not significantly different.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),[l] / [min],1.7,272186,DB00368,Norepinephrine
,2687065,plasma clearance,In patients with (n = 8) and without (n = 8) neuropathy forearm venous plasma noradrenaline and adrenaline concentrations as well as plasma clearance of adrenaline based on arterial sampling (1.7 vs 2.1 l/min) were not significantly different.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),[l] / [min],2.1,272187,DB00368,Norepinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,2.7,272188,DB00368,Norepinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,2.2,272189,DB00368,Norepinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,3.7,272190,DB00368,Norepinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,2.9,272191,DB00368,Norepinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,6.5,272192,DB00368,Norepinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,4.7,272193,DB00368,Norepinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,18,272194,DB00368,Norepinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,10,272195,DB00368,Norepinephrine
,2687065,space of distribution,The unchanged plasma clearance and the prolonged initial halftime and mean sojourn time of adrenaline in plasma suggest that adrenaline is distributed in a larger volume in Type 1 diabetic patients with neuropathy as compared to patients without neuropathy (estimated space of distribution 29 vs 20 l).,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),l,29,272196,DB00368,Norepinephrine
,2687065,space of distribution,The unchanged plasma clearance and the prolonged initial halftime and mean sojourn time of adrenaline in plasma suggest that adrenaline is distributed in a larger volume in Type 1 diabetic patients with neuropathy as compared to patients without neuropathy (estimated space of distribution 29 vs 20 l).,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),l,20,272197,DB00368,Norepinephrine
